<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">101496</article-id><article-id pub-id-type="doi">10.7554/eLife.101496</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Specific proteolysis mediated by a p97-directed proteolysis-targeting chimera (p97-PROTAC)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Salinas-Rebolledo</surname><given-names>Constanza</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6220-504X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Blesa</surname><given-names>Javier</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4257-1325</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Valenzuela-Nieto</surname><given-names>Guillermo</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Schwefel</surname><given-names>David</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2945-0908</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>López-González del Rey</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Méndez-Ruette</surname><given-names>Maxs</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Burkhalter</surname><given-names>Janine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Carrazana</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Díaz-Tejeda</surname><given-names>Francisca</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Arias Catalán</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Cappelli Leon</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Salvadores</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Bátiz</surname><given-names>Luis Federico</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Jara</surname><given-names>Ronald</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0005-2861-3911</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Obeso</surname><given-names>José A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Chana-Cuevas</surname><given-names>Pedro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9946-3299</contrib-id><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Sapkota</surname><given-names>Gopal P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9931-3338</contrib-id><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rojas-Fernandez</surname><given-names>Alejandro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6004-5425</contrib-id><email>alejandro.rojas@uach.cl</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/029ycp228</institution-id><institution>Institute of Medicine, Faculty of Medicine, Universidad Austral de Chile</institution></institution-wrap><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rk6g530</institution-id><institution>HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04jrwm652</institution-id><institution>Biotechnological Exploration Laboratory, Health Care Science Faculty, Universidad San Sebastian</institution></institution-wrap><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v4gjf40</institution-id><institution>Technische Universität Berlin, Chair of Bioanalytics</institution></institution-wrap><addr-line><named-content content-type="city">Berlin</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v0qd864</institution-id><institution>Programa de Doctorado en Biomedicina, Facultad de Medicina, Universidad de los Andes</institution></institution-wrap><addr-line><named-content content-type="city">Santiago</named-content></addr-line><country>Chile</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pn44t17</institution-id><institution>Neurodegenerative Diseases Laboratory, Center for Biomedicine, Universidad Mayor</institution></institution-wrap><addr-line><named-content content-type="city">Temuco</named-content></addr-line><country>Chile</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/029ycp228</institution-id><institution>Immunoepigenetics Laboratory, Institute of Biochemistry and Microbiology, Faculty of Sciences, Universidad Austral de Chile</institution></institution-wrap><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v0qd864</institution-id><institution>Neuroscience Program, Centro de Investigación e Innovación Biomédica (CiiB) &amp; School of Medicine, Facultad de Medicina, Universidad de los Andes</institution></institution-wrap><addr-line><named-content content-type="city">Santiago</named-content></addr-line><country>Chile</country></aff><aff id="aff9"><label>9</label><institution>IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy</institution><addr-line><named-content content-type="city">Santiago</named-content></addr-line><country>Chile</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ma57s91</institution-id><institution>CETRAM &amp; Faculty of Medical Science Universidad de Santiago de Chile</institution></institution-wrap><addr-line><named-content content-type="city">Santiago</named-content></addr-line><country>Chile</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03h2bxq36</institution-id><institution>Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Sir James Black Centre</institution></institution-wrap><addr-line><named-content content-type="city">Dundee</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff12"><label>12</label><institution>Berking Biotechnology SpA</institution><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff><aff id="aff13"><label>13</label><institution>Berking Bioscience GmbH</institution><addr-line><named-content content-type="city">Hamburg</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ye</surname><given-names>Yihong</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Campelo</surname><given-names>Felix</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04n0g0b29</institution-id><institution>Universitat Pompeu Fabra</institution></institution-wrap><country>Spain</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>26</day><month>11</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e101496</elocation-id><history><date date-type="received" iso-8601-date="2024-07-17"><day>17</day><month>07</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-10-30"><day>30</day><month>10</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2024-03-09"><day>09</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.08.584142"/></event></pub-history><permissions><copyright-statement>© 2025, Salinas-Rebolledo et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Salinas-Rebolledo et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-101496-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-101496-figures-v2.pdf"/><abstract><p>The p97 protein is a member of the AAA+ family of ATPases. This protein is encoded by the <italic>VCP</italic> gene. It is a mechanoenzyme that uses energy from ATP hydrolysis to promote protein unfolding and segregation actively. The unfolded products are subsequently presented to the 26S proteasome for degradation. p97 substrate recognition is mediated by adaptors, which interact with substrates directly or indirectly through ubiquitin modifications, resulting in substrate funnelling into the central pore of the p97 hexamer and unfolding. Here, we engineered synthetic adaptors to target specific substrates to p97, using the extraordinary intracellular binding capabilities of camelid nanobodies fused to the UBX domain of the p97 adaptor protein Fas-associated factor-1 (FAF1). In such a way, we created a p97-directed proteolysis-targeting chimera (PROTAC), representing a novel and unique E3 ubiquitin ligase-independent strategy to promote specific proteolysis. All functional assays were performed in human cell lines to evaluate the system’s efficacy and specificity in a physiologically relevant context.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>PROTAC</kwd><kwd>nanobody</kwd><kwd>alpaca</kwd><kwd>P97</kwd><kwd>VCP</kwd><kwd>ubiquitin-free</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016nafs32</institution-id><institution>Fondo Nacional de Desarrollo Científico y Tecnológico</institution></institution-wrap></funding-source><award-id>1200427</award-id><principal-award-recipient><name><surname>Rojas-Fernandez</surname><given-names>Alejandro</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016nafs32</institution-id><institution>Fondo Nacional de Desarrollo Científico y Tecnológico</institution></institution-wrap></funding-source><award-id>3220635</award-id><principal-award-recipient><name><surname>Valenzuela-Nieto</surname><given-names>Guillermo</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016nafs32</institution-id><institution>Fondo Nacional de Desarrollo Científico y Tecnológico</institution></institution-wrap></funding-source><award-id>13220075</award-id><principal-award-recipient><name><surname>Valenzuela-Nieto</surname><given-names>Guillermo</given-names></name><name><surname>Rojas-Fernandez</surname><given-names>Alejandro</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ap3w078</institution-id><institution>Agencia Nacional de Investigación y Desarrollo</institution></institution-wrap></funding-source><award-id>21170632</award-id><principal-award-recipient><name><surname>Salinas-Rebolledo</surname><given-names>Constanza</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ap3w078</institution-id><institution>Centro Ciencia ficos y Tecnológicos de Excelencia de ANID</institution></institution-wrap></funding-source><award-id>FB210008</award-id><principal-award-recipient><name><surname>Rojas-Fernandez</surname><given-names>Alejandro</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01hhn8329</institution-id><institution>Max Planck Society</institution></institution-wrap></funding-source><award-id>190011</award-id><principal-award-recipient><name><surname>Rojas-Fernandez</surname><given-names>Alejandro</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>ISCIII Miguel Servet Program</institution></institution-wrap></funding-source><award-id>CP19/00200</award-id><principal-award-recipient><name><surname>Blesa</surname><given-names>Javier</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>ISCIII Miguel Servet Program</institution></institution-wrap></funding-source><award-id>FIS PI20/00496</award-id><principal-award-recipient><name><surname>Blesa</surname><given-names>Javier</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Becas Santander Iberoamerica Investigacion 2018/2019</institution></institution-wrap></funding-source><award-id>S2017/BMD-3700</award-id><principal-award-recipient><name><surname>López-González del Rey</surname><given-names>Natalia</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/018mejw64</institution-id><institution>German Research Foundation (DFG) Emmy Noether Programme</institution></institution-wrap></funding-source><award-id>SCHW1851/1-1</award-id><principal-award-recipient><name><surname>Schwefel</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution>FONIS EU-LAC</institution></institution-wrap></funding-source><award-id>T010047</award-id><principal-award-recipient><name><surname>Salinas-Rebolledo</surname><given-names>Constanza</given-names></name><name><surname>Chana-Cuevas</surname><given-names>Pedro</given-names></name><name><surname>Obeso</surname><given-names>José A</given-names></name><name><surname>Blesa</surname><given-names>Javier</given-names></name><name><surname>López-González del Rey</surname><given-names>Natalia</given-names></name><name><surname>Rojas-Fernandez</surname><given-names>Alejandro</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Synthetic adaptors combining camelid nanobodies with the UBX domain of the p97 adaptor FAF1 enable targeted substrate delivery to p97, establishing an E3 ubiquitin ligase-independent mechanism for selective protein degradation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The ubiquitin-proteasome system (UPS) plays a central role in maintaining proteostasis by regulating protein abundance. This regulation is mediated by specific E3 ubiquitin ligases, which catalyze ubiquitin chain formation on the substrates, inducing their proteasome-mediated degradation (<xref ref-type="bibr" rid="bib85">Tara et al., 1974</xref>; <xref ref-type="bibr" rid="bib15">Ciechanover, 1994</xref>; <xref ref-type="bibr" rid="bib59">McNaught et al., 2001</xref>; <xref ref-type="bibr" rid="bib80">Schmidt et al., 2021</xref>). The UPS as an efficient natural negative-regulatory mechanism has inspired the development of the proteolysis-targeting chimera (PROTAC) technology, involving synthetic heterobifunctional molecules able to recruit a protein of interest (POI) to a ubiquitin E3 ligase to induce its proteasomal degradation (<xref ref-type="bibr" rid="bib9">Bondeson et al., 2015</xref>; <xref ref-type="bibr" rid="bib79">Sakamoto et al., 2001</xref>; <xref ref-type="bibr" rid="bib38">Holland et al., 2012</xref>; <xref ref-type="bibr" rid="bib77">Röth et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Macartney et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Clift et al., 2018</xref>; <xref ref-type="bibr" rid="bib3">Békés et al., 2022</xref>; <xref ref-type="bibr" rid="bib86">Tomoshige et al., 2017</xref>; <xref ref-type="bibr" rid="bib87">Tomoshige and Ishikawa, 2021</xref>; <xref ref-type="bibr" rid="bib73">Pankey, 1986</xref>; <xref ref-type="bibr" rid="bib42">Ibrahim et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Paiva and Crews, 2019</xref>; <xref ref-type="bibr" rid="bib90">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Békés et al., 2022</xref>).</p><p>The nature of PROTACs varies from small molecules to protein domains and antibody fragments.</p><p>Several camelid nanobodies are capable of binding intracellular target proteins selectively, with a high affinity. When nanobodies are overexpressed in mammalian cells, they are also known as intrabodies (<xref ref-type="bibr" rid="bib42">Ibrahim et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Caussinus et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Fulcher et al., 2016</xref>). Nanobodies fused to ubiquitin E3 ligase substrate receptors trigger protein degradation of ectopic and endogenous targets. For instance, the AdPROM system consisting of a fusion of the E3 substrate receptor VHL with nanobodies against a range of POIs leads to the efficient degradation of endogenous POI targets (<xref ref-type="bibr" rid="bib77">Röth et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Macartney et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Fulcher et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Fulcher et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Simpson et al., 2020</xref>; <xref ref-type="bibr" rid="bib70">Ottis et al., 2017</xref>; <xref ref-type="bibr" rid="bib83">Smith et al., 2019</xref>). Nanobodies have also been engineered and fused directly to the active domains of ubiquitin E3 ligases, such as the antibody RING-mediated destruction system (ARMeD), which uses the RING finger domain of the ubiquitin E3 ligase RNF4 fused to a nanobody. A valuable feature of the ARMeD system is its independence of the endogenous ubiquitin E3 ligases (<xref ref-type="bibr" rid="bib42">Ibrahim et al., 2020</xref>).</p><p>In addition to conventional ubiquitin-dependent degradation, the AAA-type ATPase p97 assists the proteasome in the specific selection of substrate degradation in eukaryotic cells (<xref ref-type="bibr" rid="bib89">van den Boom and Meyer, 2018</xref>). The key mechanism of action involves the disassembly of protein complexes through its ATP-dependent <italic>segregase</italic> and <italic>unfoldase</italic> activity (<xref ref-type="bibr" rid="bib68">Noi et al., 2013</xref>; <xref ref-type="bibr" rid="bib69">Olszewski et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Bodnar and Rapoport, 2017</xref>; <xref ref-type="bibr" rid="bib39">Hu et al., 2020</xref>). p97 uses ATP hydrolysis as a source of energy to ‘segregate’ ubiquitylated protein complex subunits from their binding partners, or even to the unfolding of protein aggregates, such as tau amyloid fibers and exon 1 of Huntingtin (HTT) (<xref ref-type="bibr" rid="bib92">Wentink and Rosenzweig, 2023</xref>; <xref ref-type="bibr" rid="bib66">Mukkavalli et al., 2021</xref>; <xref ref-type="bibr" rid="bib78">Saha et al., 2023</xref>; <xref ref-type="bibr" rid="bib31">Ghosh et al., 2018</xref>). This action is mediated by two types of adaptors: the UBX-like domain (UBX-L, also known as the ‘ubiquitin-binding domain’ [UBD]) adaptors such as Ufd1, NLP4, p47, FAF1, SAKS, UBXD7, and UBXD8, and the UBX-only adaptors, such as p37, UBXD1, UBXD2, UBXD3, UBXD4, UBXD5, UBXD6, VCIP135, and YOD1 (<xref ref-type="bibr" rid="bib95">Ye et al., 2017</xref>; <xref ref-type="bibr" rid="bib97">Yeung et al., 2008</xref>; <xref ref-type="bibr" rid="bib45">Kloppsteck et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Meyer, 2012</xref>; <xref ref-type="bibr" rid="bib84">Stach and Freemont, 2017</xref>).</p><p>p97 also regulates ER-mitochondrial association by disassembling Mfn2 complexes upon PINK/Parkin phosphoubiquitination and the mitochondrial extraction of MARCH5. This process disrupts mitochondria-ER tethering during mitophagy, facilitating mitochondrial degradation (<xref ref-type="bibr" rid="bib58">McLelland et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Koyano et al., 2019</xref>). Additionally, p97 co-localizes with protein aggregates involved in several neurodegenerative diseases, suggesting that its <italic>segregase</italic> and <italic>unfoldase</italic> activities could be related to the proteolytic control of proteins of therapeutic interest (<xref ref-type="bibr" rid="bib29">Galindo-Moreno et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Hirabayashi et al., 2001</xref>; <xref ref-type="bibr" rid="bib65">Mizuno et al., 2003</xref>; <xref ref-type="bibr" rid="bib94">Yang and Hu, 2016</xref>; <xref ref-type="bibr" rid="bib46">Kobayashi et al., 2007</xref>; <xref ref-type="bibr" rid="bib1">Alieva et al., 2020</xref>). For instance, p97 is recruited to poly-Q aggregates in vitro and to inclusion-positive neurons in Huntington’s disease patients (<xref ref-type="bibr" rid="bib66">Mukkavalli et al., 2021</xref>; <xref ref-type="bibr" rid="bib37">Hirabayashi et al., 2001</xref>). Abnormal protein aggregation is observed in several pathologies such as inclusion body myopathy associated with Paget’s disease of bone and frontotemporal dementia (IBMPFD), Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, and Parkinson’s disease (<xref ref-type="bibr" rid="bib1">Alieva et al., 2020</xref>; <xref ref-type="bibr" rid="bib91">Watts et al., 2004</xref>; <xref ref-type="bibr" rid="bib24">Falcão de Campos and de Carvalho, 2019</xref>; <xref ref-type="bibr" rid="bib33">Gonzalez et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">González-Pérez et al., 2012</xref>). Ubiquitin is often found as a resident protein within aggregates related to neurodegenerative diseases, suggesting potential dysfunction of ubiquitin-mediated degradation signaling (<xref ref-type="bibr" rid="bib2">Alnot and Frajman, 1992</xref>; <xref ref-type="bibr" rid="bib40">Huang and Figueiredo-Pereira, 2010</xref>; <xref ref-type="bibr" rid="bib20">Donaldson et al., 2003</xref>; <xref ref-type="bibr" rid="bib25">Fernández-Sáiz and Buchberger, 2010</xref>).</p><p>Motivated by these characteristics, we engineered a synthetic p97 adapter by fusing the UBX domain of the FAF1 protein to camelid nanobodies, to assemble a novel p97-based PROTAC (<bold>p97-PROTAC</bold>) technology. This new chimera efficiently targets proteins for segregation and proteasome-mediated degradation in a ubiquitin-independent manner.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>p97-PROTAC subcellular recruitment and activity in cells</title><p>p97 adaptors and cofactors lead to the specific recognition of ubiquitin-modified and unmodified substrates, enabling their simultaneous entry into the central pore of p97 hexamers, followed by unfolding and subsequent proteasomal degradation (<xref ref-type="bibr" rid="bib11">Caffrey et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Bodnar and Rapoport, 2017</xref>). We hypothesized that p97 adaptors could be engineered to target non-natural substrates of clinical interest for degradation. Thus, we generated a synthetic chimera consisting of the UBX domain of the p97 adapter FAF1 fused via a linker to a GFP-specific camelid nanobody (UBX-Nb<sup>(GFP)</sup>), which is capable of recognizing both GFP- and yellow fluorescent protein (YFP)-tagged proteins, to yield a novel PROTAC based on p97 activity (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; amino acid sequence in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>p97-mediated proteasome degradation.</title><p>(<bold>A</bold>) Schematic representation of p97 presenting ubiquitinated proteins to the proteasome via a UBX domain-containing adaptor (top). The p97-PROTAC system, consisting of a UBX domain fused to a nanobody (Nb) that recruits substrates for p97-mediated segregation, unfolding, and proteasomal-mediated degradation (bottom). (<bold>B</bold>) p97-PROTAC (UBX-Nb<sup>(GFP)</sup>) recognizes GFP-tagged proteins at different cellular locations. HeLa cells were seeded on coverslips and co-transfected with UBX-Nb<sup>(GFP)</sup> and GFP-Coilin, GFP-Emerin, and GFP-ETV1. Cells were fixed and immunostained with anti-myc tag to verify the expression of UBX-Nb<sup>(GFP)</sup>. Colocalization was evaluated using ImageJ/Fiji with the Coloc 2 plugin, obtaining Pearson correlation coefficient (<bold>R</bold>) values as follows: GFP-Emerin=0.95, GFP-Coilin=0.96, and GFP-ETV1=0.95. (<bold>C</bold>) Western blot analysis of GFP-Coilin degradation by transfection with p97-PROTAC (UBX-Nb<sup>(GFP)</sup>). (<bold>D</bold>) Quantification of C. (<bold>E</bold>) Western blot analysis of GFP-Emerin degradation by transfection with p97-PROTAC (UBX-Nb<sup>(GFP)</sup>). (<bold>F</bold>) Quantification of E. (<bold>G</bold>) Western blot analysis of GFP-ETV1 degradation by transfection with p97-PROTAC (UBX-Nb<sup>(GFP)</sup>). (H) Quantification of G, <italic>GFP-Coilin: 2 μg ‘p-value’ 0.0011 (**), 4</italic> μg ‘<italic>p-value’ 0.0009 (***). GFP-Emerin: 2 μg ‘p-value’ 0.0130 (*), 4</italic> μg ‘<italic>p-value’ 0.0059 (**). GFP-ETV1: 2 μg ‘p-value’ 0.0041 (**), 4</italic> μg ‘<italic>p-value’ 0.0020 (**</italic>). Western blots were quantified and statistically analyzed using a Student’s t-test. p&lt;0.05 compared to controls. n=3.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw Western blot images supporting GFP-Coilin, GFP-Emerin, and GFP-ETV1 degradation assays.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Annotated Western blot images indicating protein bands corresponding to GFP-Coilin, GFP-Emerin, and GFP-ETV1 degradation assays.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101496-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>p97-PROTAC sequence, colocalization analysis, and controls confirming UBX-dependent degradation.</title><p>(<bold>A</bold>) Amino acid sequence of human FAF1 UBX domain and synthetic p97 PROTAC chimera. (<bold>B–D</bold>) Histogram visualization of the colocalization of GFP-Coilin (<bold>B</bold>), GFP-Emerin (<bold>C</bold>), or GFP-ETV1 (<bold>D</bold>) and the Myc-tagged UBX-nanobody targeting GFP in HeLa cells. (<bold>E–G</bold>) HeLa cells were co-transfected with GFP-Coilin (<bold>E</bold>), GFP-ETV1 (<bold>F</bold>) or GFP-Emerin (<bold>G</bold>) with an empty vector or increasing concentrations of UBX-Nb (Neg.ctrl) vector. Protein degradation was analyzed by western blot. (<bold>H–I</bold>) Control experiment showing the localization of Myc-UBX-Nb(GFP) in HeLa cells co-transfected with free GFP (<bold>H</bold>) or empty vector (<bold>I</bold>).</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Raw Western blots showing UBX-dependent degradation using an alternative nanobody as a control.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Annotated Western blots showing UBX-dependent degradation using an alternative nanobody as a control.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig1-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101496-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Using fluorescence microscopy, we then evaluated if the UBX-Nb<sup>(GFP)</sup> could recognize GFP-fusion proteins with different subnuclear localizations by analyzing its recruitment to a group of differentially located targets: (i) GFP-Coilin (nuclear and Cajal bodies), (ii) GFP-Emerin (a type II integral membrane protein residing principally at the inner nuclear membrane, with occasional reports of ER localization likely due to overexpression or cell-type specific contexts) (<xref ref-type="bibr" rid="bib93">Xie et al., 2024</xref>), and (ii) GFP-ETV1 (nuclear transcription factor) in HeLa cells. Our results demonstrated efficient recruitment of UBX-Nb<sup>(GFP)</sup> to these diverse nuclear locations (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Additionally, we confirmed its colocalization using the Pearson correlation coefficient. High Pearson correlation values in our analysis further support the specific colocalization of UBX-Nb<sup>(GFP)</sup> with these nuclear proteins. Furthermore, we generated histograms representing the fluorescence intensity profiles of UBX-Nb<sup>(GFP)</sup> and the target proteins across selected regions of interest, providing a visual confirmation of their spatial overlap (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–D</xref>).</p><p>To further assess whether the UBX-Nb<sup>(GFP)</sup> construct exhibits any intrinsic subcellular localization pattern, we co-expressed Myc-UBX-Nb<sup>(GFP)</sup> together with either free GFP or an empty vector. Under both conditions, UBX-Nb<sup>(GFP)</sup> displayed a diffuse cytoplasmic and nuclear distribution without enrichment in specific organelles (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H and I</xref>). These results confirm that the localization of UBX-Nb<sup>(GFP)</sup> observed in <xref ref-type="fig" rid="fig1">Figure 1B</xref> is due to its recruitment to GFP-tagged target proteins, and not to an inherent localization bias of the construct.</p><p>Next, we studied the effect of Myc-tagged UBX-Nb<sup>(GFP)</sup> PROTAC expression on the levels of GFP-Coilin, GFP-Emerin, and GFP-ETV1. We observed a significant reduction in the levels of all GFP-tagged target proteins with increasing expression of Myc-UBX-Nb<sup>(GFP)</sup>, indicating that the p97-PROTAC-UBX-Nb<sup>(GFP)</sup> is sufficient to trigger specific proteolysis of target proteins (<xref ref-type="fig" rid="fig1">Figure 1C–H</xref>). Consistently, no degradation was observed when the GFP nanobody was replaced by a negative control nanobody (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E–G</xref>). Therefore, these findings suggested that p97-PROTAC could be an alternative targeted protein degradation approach to the conventional ubiquitin ligase-based PROTACs and might be useful for the degradation of large protein complexes, integral membrane protein at the inner nuclear membrane, and toxic aggregates due to its <italic>unfoldase</italic> and <italic>segregase</italic> activities.</p></sec><sec id="s2-2"><title>Specific degradation of proteins within liquid-liquid phase separation structures</title><p>We sought to test the efficacy of the p97-PROTAC system for the degradation of proteins whose expression was driven by endogenous promoters. To further investigate its ability to induce degradation of proteins within aggregates and packed in highly condensed regions, we chose 53BP1 as the target protein (encoded by the <italic>TP53BP1</italic> gene), as it is a well-known component of liquid-liquid phase separation (LLPS) structures (<xref ref-type="bibr" rid="bib74">Pessina et al., 2019</xref>; <xref ref-type="bibr" rid="bib98">Zhang et al., 2022</xref>).</p><p>First, we generated a knock-in (KI) cell line by fusing a YFP to the N-terminus of the endogenous 53BP1 protein using CRISPR/Cas9 technology. 24 hr after transfection with a forward and reverse gRNA and the donor vector, Cas9 D10A nickase was induced with doxycycline. Single YFP-positive cell clones were isolated by cell sorting (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Natural DNA damage that occurs during DNA replication induces the accumulation of 53BP1 fluorescence signal in distinct nuclear foci. The foci are typical for 53BP1, which has been described to accumulate in nuclear bodies during the G1 phase of the cell cycle (<xref ref-type="bibr" rid="bib53">Lukas et al., 2011</xref>). The YFP-53BP1 KI clones were analyzed by fluorescence microscopy, and a heterozygote clone was selected (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Targeting liquid-liquid phase separation proteins by a p97-PROTAC.</title><p>(<bold>A</bold>) Strategy for inserting a yellow fluorescent protein (YFP) tag on the N-terminus of the 53BP1 gene in U2OS SEC-C cells using CRISPR/Cas9 D10A. (<bold>B</bold>) Selected knock-in (KI) YFP-53BP1 clones isolated via flow cytometry. Clones were confirmed via fluorescence microscopy (GE Deltavision Widefield). (<bold>C</bold>) Super-resolution images obtained with a Delta Vision OMX V4 structured illumination microscope (3D-SIM). (<bold>D</bold>) Immunofluorescence against 53BP1 (red) and colocalization with YFP-53BP1 in KI cells. Images were obtained using a Delta Vision OMX V4 structured illumination microscope (3D-SIM). (<bold>E</bold>) Recruitment of the p97-PROTAC UBX-Nb<sup>(GFP)</sup> (red) to YFP-53BP1 (green) within liquid-liquid phase separation structures. Data were obtained with a high-content CellDiscoverer 7. UBX-Nb<sup>(GFP)</sup> was detected using its myc-tag. (<bold>F</bold>) Western blot analysis of YFP-53BP1 degradation by UBX-Nb<sup>(GFP)</sup> transfection in the KI U2OS cells. (<bold>G</bold>) Quantification of F, ‘<italic>p-value’ 0.0071 (**</italic>). Western blots were quantified and statistically analyzed using a Student’s t-test. p&lt;0.05 compared to controls. n=3.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw Western blots showing p97-PROTAC–mediated degradation of YFP-53BP1 in KI U2OS cells.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Annotated Western blots indicating YFP-53BP1 degradation in KI U2OS cells transfected with p97-PROTAC.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig2-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101496-fig2-v2.tif"/></fig><p>To further characterize 53BP1 foci in U2OS YFP-53BP1 (KI) cells, we employed structured illumination microscopy (SIM) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). We evaluated the localization of the YFP-53BP1 KI and endogenous 53BP1 by SIM and demonstrated the expected location for the KI fusion (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Accordingly, the YFP-53BP1 KI cell line fully recapitulated the localization of endogenous 53BP1, and the endogenous 53BP1 promoter controls the YFP-53BP1 KI expression.</p><p>53BP1 nuclear bodies have been described as membrane-less organelles, organized by LLPS. Hence, we used the YFP-53BP1 KI cells as a model to study the recruitment and function of the p97-PROTAC UBX-Nb<sup>(GFP)</sup> to target LLPS. We observed that the UBX-Nb<sup>(GFP)</sup> construct was successfully recruited to nuclear foci characterized by the 53BP1 location (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Importantly, UBX-Nb<sup>(GFP)</sup> expression significantly reduced 53BP1 levels, suggesting that our p97-PROTAC technology can specifically trigger the degradation of proteins within LLPS compartments (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>).</p></sec><sec id="s2-3"><title>Endogenous p97 expression in the brain</title><p>Conventional PROTAC technologies exploit the activity of E3 ubiquitin ligases and accordingly require the expression of a suitable ligase to cause target ubiquitination and degradation. To assess whether p97 could likewise be available for our approach, we studied the endogenous expression of p97 in the brains of animal models. Immunohistochemistry was performed using a rabbit polyclonal anti-p97 antibody (HPA012728, Sigma-Aldrich, whose specificity has been reported in the Human Protein Atlas). Consistent with these data, we observed ubiquitous expression in the cortex of nonhuman primates (NHPs), mice, and rats. Additionally, endogenous p97 expression was observed in the hippocampus and substantia nigra pars compacta (SNpc) of mice and rats, the major pathological sites in Alzheimer’s and Parkinson’s disease, respectively (<xref ref-type="fig" rid="fig3">Figure 3</xref>; <xref ref-type="bibr" rid="bib32">Gómez-Isla and Frosch, 2022</xref>; <xref ref-type="bibr" rid="bib7">Blesa et al., 2022</xref>). Unfortunately, no tissue samples of NHP were available for other brain regions. Thus, p97 is endogenously expressed in regions of clinical interest that are affected by neurodegenerative diseases. Ultimately, the <italic>segregase</italic> and <italic>unfoldase</italic> activity of p97 in the brain could be advantageous for p97-PROTAC-based targeted degradation of toxic protein aggregates, especially for neurodegenerative diseases.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Endogenous p97 expression in brain tissue.</title><p>Immunohistochemistry against p97 in brain tissue sections from nonhuman primates (Nhp) <italic>Macaca fascicularis</italic>, rat (<italic>Sprague-Dawley</italic>), and mouse (C57BL6/C). p97 expression was detected in substantia nigra pars compacta (SNpc), hippocampal, and cortical neurons. n=4.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101496-fig3-v2.tif"/></fig></sec><sec id="s2-4"><title>Structural and functional characterization of the p97-PROTAC mechanism</title><p>To gain insight into the structure of substrate-bound p97-PROTAC in the context of the p97 assembly, an AlphaFold2-based model of the p97-PROTAC/GFP-complex bound to p97 was generated (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; see Materials and methods for details of the modeling procedure). After manually adjusting the conformation of the flexible linker between PROTAC UBX and Nb<sup>(GFP)</sup> moieties, the model shows that PROTAC-recruited GFP can access the central p97 pore (&lt;15 Å distance between the pore entrance and the closest GFP residue) (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Consistent with the model, we determined that GFP alone, a barrel conformation protein of 28 kDa, can be recruited by the p97-PROTAC and is efficiently processed for degradation (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Molecular model and degradation activity of p97-PROTAC.</title><p>(<bold>A</bold>) Model representations of the FAF1 UBX domain (purple), UBX-Nb<sup>(GFP)</sup> (blue), GFP (green), and the p97 hexamer (light gray cartoon with semitransparent molecular surface representation). (<bold>B</bold>) A magnified view of the model shown in A. (<bold>C</bold>) GFP monomer was co-transfected with UBX-Nb <sup>(GFP)</sup> or empty vector in HeLa cells. Protein degradation was analyzed by western blot analysis. (<bold>D</bold>) Quantification of C, ‘<italic>p-value’ 0.0007 (***</italic>). (<bold>E</bold>) GFP monomer was co-transfected with UBX-Nb<sup>(GFP)</sup> or empty vector in HeLa cells, after 24 hr, the cells were incubated with DMSO or the proteasome inhibitor MG132 (25 µM final concentration) for 4 hr. Protein degradation was analyzed by western blot. (<bold>F</bold>) Quantification of E, ‘<italic>p-value’ DMSO treatment 0.0120 (*), ‘p-value’ MG132 treatment 0.7776 (ns</italic>). (<bold>G</bold>) p97 was silenced by transfection with <italic>VCP</italic>-siRNA in HeLa cells. Subsequently, the cells were transfected with GFP-Emerin and either the empty vector or UBX-Nb<sup>(GFP)</sup> vector. Protein degradation was analyzed by western blot analysis. (<bold>H</bold>) Quantification of GFP-Emerin in UBX-Nb<sup>(GFP)</sup> cells treated with either siNT control or a <italic>VCP</italic>-siRNA, ‘<italic>p-value’ 0.0114 (*</italic>). (<bold>I</bold>) Quantification of the UBX-Nb<sup>(GFP)</sup> (myc-tag) in UBX-Nb<sup>(GFP)</sup> cells treated with either siNT control or a <italic>VCP</italic>-siRNA, ‘<italic>p-value’ 0.0775 (ns</italic>). (<bold>J</bold>) HeLa cells co-transfected with GFP-Emerin and either empty vector or UBX-Nb<sup>(GFP)</sup>; in addition, the cells were treated with the E1 ubiquitin inhibitor PYR-41 (50 µM) for 4 hr at 37°C. Subsequently, total proteins were extracted, and protein degradation was analyzed by western blot. (<bold>K</bold>) Quantification of J, ‘<italic>p-value’ DMSO treatment 0.0009 (***), ‘p-value’ PYR-41 treatment 0.0003 (***</italic>). (<bold>L</bold>) GFP-Emerin was co-transfected with UBX-Nb<sup>(GFP)</sup> or empty vector in HeLa cells, after 24 hr the cells were incubated with DMSO (as control) or the p97 inhibitor CB-5083 (4 µM final concentration) for 6 hr. Protein degradation was analyzed by western blot using total proteins. (<bold>M</bold>) Quantification of L, ‘<italic>p-value’ DMSO treatment 0.0071 (**), ‘p-value’ CB-5083 treatment 0.0139 (*</italic>). Western blots were quantified and statistically analyzed using a Student’s t-test. p&lt;0.05 compared to controls. n=3.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw Western blots showing p97-PROTAC–mediated degradation using inhibitors and siRNA controls.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig4-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Annotated Western blots showing p97-PROTAC–mediated degradation under inhibitor and siRNA conditions.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig4-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101496-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Validation of p97-dependent degradation and evaluation of PYR41 treatment.</title><p>(<bold>A</bold>) HeLa cells were co-transfected with a vector expressing anti-GFP nanobody fused to a myc-tag (Myc-Nb-anti-GFP) along with either an empty vector or increasing concentrations of p97-GFP. The degradation of Myc-Nb-anti-GFP was analyzed by western blot. (<bold>B</bold>) Quantification of panel H: 2 μg (p-value = 0.0410, *), 4 μg (p-value = 0.0063, **). (<bold>C</bold>) HeLa cells were incubated with different concentrations of PYR-41 (a cell-permeable irreversible inhibitor of ubiquitin-activating enzyme E1) for 4 hr. Subsequently, total cellular proteins were extracted, and western blot analyses were performed. Nitrocellulose membranes were incubated with the primary antibodies anti-p53 and anti-ubiquitin antibody. DMSO was used as a control. n=2.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Raw Western blots showing p97-dependent degradation and PYR41 treatment effects.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig4-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Annotated Western blots indicating protein bands for p97-dependent degradation and PYR41 treatment effects.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig4-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101496-fig4-figsupp1-v2.tif"/></fig></fig-group><p>To test the mechanism underlying by which the GFP became degraded, we co-transfected cells with GFP and either an empty vector or with the p97-PROTAC UBX-Nb<sup>(GFP)</sup>. After 20 hr, cells were treated with the proteasome inhibitor MG132 or DMSO as control. Upon MG132 treatment, we observed a full rescue of GFP protein levels. Therefore, by using a small substrate such as GFP as a model, we demonstrated that p97-PROTAC proteolytic activity relies on proteasome-mediated degradation (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>).</p><p>To determine whether p97 is directly involved in the degradation process mediated by the p97-PROTAC system, we compared cells co-transfected with the Myc-tagged nanobody anti-GFP (Nb-GFP-Myc) and a p97-GFP vector to cells co-transfected with Nb-GFP-Myc and an empty vector. Notably, cells expressing p97-GFP exhibited a significant reduction in Myc-tagged Nb-GFP levels. In contrast, cells transfected with the empty vector showed no effect on Myc-tag levels (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>). These results provide evidence supporting the direct role of p97 in facilitating the degradation mechanism mediated by the p97-PROTAC system.</p><p>To further validate these observations, we depleted p97 by transfecting cells with siRNAs targeting the <italic>VCP</italic> gene (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Upon p97 knockdown, a significant rescue of GFP-Emerin protein levels was observed, concomitant with an increase of the levels of the p97-PROTAC UBX-Nb<sup>(GFP)</sup> (<xref ref-type="fig" rid="fig4">Figure 4H and I</xref>), indicating that the PROTAC UBX-Nb<sup>(GFP)</sup> itself may also act as a substrate for p97.</p><p>To test the hypothesis that p97-PROTAC action is a ubiquitination-independent process, we globally inhibited ubiquitination using PYR41, a cell-permeable, irreversible inhibitor of the ubiquitin-activating enzyme E1 activity. First, we demonstrated that PYR41 was able to stabilize p53 in HeLa cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Next, we used GFP-Emerin as a substrate model and treated the cell with either DMSO or 50 µM of PYR41 for 4 hr. Consistent with our hypothesis, no inhibition of GFP-Emerin degradation was observed by the PYR41 treatment (<xref ref-type="fig" rid="fig4">Figure 4J and K</xref>). Finally, we investigated whether the activities of p97 were required for the substrate-mediated degradation triggered by p97-PROTAC UBX-Nb<sup>(GFP)</sup>. We tested the degradation of GFP-Emerin in HeLa cells treated with either DMSO or CB-5083, a potent inhibitor of the ATPase activity of p97. As an internal control, we measured the levels of CHOP, a sensor of ER stress known to be induced by p97 inhibitors <xref ref-type="fig" rid="fig4">Figure 4L</xref>. Surprisingly, we did not observe inhibition of degradation of GFP-Emerin in cells treated with CB-5083, despite the increase in CHOP levels (<xref ref-type="fig" rid="fig4">Figure 4M</xref>). Thus, our results show that p97-PROTAC targets proteins for proteasomal-mediated degradation by a ubiquitin-independent mechanism.</p></sec><sec id="s2-5"><title>Degradation of proteins of clinical interest by a p97-based PROTAC</title><p>A hallmark for several neurodegenerative diseases is the accumulation of toxic aggregates in the intra- or extracellular space (<xref ref-type="bibr" rid="bib76">Ross and Poirier, 2004</xref>). PROTAC technology has the potential to become a new therapeutic approach for proteotoxic diseases (<xref ref-type="bibr" rid="bib47">Konstantinidou et al., 2019</xref>). High levels of ubiquitin are often found in intracellular aggregates, suggesting that ubiquitination-mediated proteasomal degradation may be partially impaired (<xref ref-type="bibr" rid="bib30">Galves et al., 2019</xref>; <xref ref-type="bibr" rid="bib28">Gai et al., 2000</xref>). Targeting p97 to toxic aggregates could potentially contribute to the clearance of aggregates by inducing segregation, unfolding, and proteasomal degradation simultaneously.</p><p>To evaluate the capacity of the p97-PROTAC system to degrade toxic aggregates, we tested two clinically relevant proteins: HTT and α-synuclein, which are known to form toxic aggregates. In the first experiment, we used GFP-fusion plasmids containing exon 1 of HTT with either 23 CAG repeats (EGFP-HTT Q23, wild-type HTT) or 74 CAG repeats (EGFP-HTT Q74, mutant HTT). We observed efficient degradation of both EGFP-HTT Q23 and EGFP-HTT Q74 by the p97-PROTAC UBX-Nb<sup>(GFP)</sup>, as demonstrated in <xref ref-type="fig" rid="fig5">Figure 5D and E</xref>, respectively. Also, in both cases, co-localization of the p97-PROTAC with EGFP-HTT was evident within the cells (<xref ref-type="fig" rid="fig5">Figure 5C and F</xref>). Notably, EGFP-HTT Q74 transfection resulted in the formation of aggregates, and the p97-PROTAC was observed to co-localize with these aggregates, supporting the direct interaction of the p97-PROTAC with the target protein, regardless of its aggregation state.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Degradation of Huntingtin wild type and mutant with p97-PROTAC UBX-Nb<sup>(GFP)</sup>.</title><p>HeLa cells were transiently co-transfected with HTT GFP-tagged plasmids containing either 23 CAG repeats (EGFP-HTT<sup>Q23</sup>-wild-type HTT), 74 CAG repeats (EGFP-HTT<sup>Q74</sup>: mutant HTT), or 24 CAG repeats (EGFP-HTT<sup>Q24</sup>). (<bold>A</bold>) Cells were co-transfected with GFP-HTT<sup>Q23</sup> and increasing amounts of the p97 PROTAC UBX-Nb<sup>(GFP)</sup>, degradation was determined by western blot analysis. (<bold>B</bold>) Quantification of A, <italic>2 μg ‘p-value’ 0.0041 (**), 4 μg ‘p-value’ 0.0014 (**</italic>). (<bold>C</bold>) Immunofluorescence showing the recruitment of p97 PROTAC UBX-Nb<sup>(GFP)</sup> to GFP-HTT<sup>Q23</sup>. (<bold>D</bold>) HeLa cells were co-transfected with GFP-HTT<sup>Q74</sup> and increasing amounts of the p97 PROTAC UBX-Nb<sup>(GFP)</sup>, degradation was determined by western blot analysis. (<bold>E</bold>) Quantification of D, <italic>2 μg ‘p-value’ 0.0016 (**), 4 μg ‘p-value’ 0.0003 (***</italic>). (<bold>F</bold>) Immunofluorescence to demonstrate the recruitment of p97 PROTAC UBX-Nb<sup>(GFP)</sup> to GFP-HTT<sup>Q74</sup>. Western blots were quantified and statistically analyzed using a Student’s t-test. p&lt;0.05 compared to controls. n=3.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw Western blots showing p97-PROTAC–mediated degradation of GFP-HTTQ23 and GFP-HTTQ74.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig5-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Annotated Western blots indicating protein bands for p97-PROTAC–mediated degradation of GFP-HTTQ23 and GFP-HTTQ74.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig5-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101496-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>HeLa cells were co-transfected with GFP-HTT Q24 and either the p97-PROTAC UBX-Nb(GFP) or an empty vector.</title><p>High-molecular-weight aggregates and protein degradation were analyzed by western blot. Western blots were quantified and statistically analyzed using a Student’s t-test. p&lt;0.05 compared to controls. n=3.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Raw Western blots showing p97-PROTAC effects on GFP-HTTQ24 degradation and aggregate levels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig5-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Annotated Western blots indicating protein bands for GFP-HTTQ24 degradation and aggregate analysis under p97-PROTAC treatment.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig5-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101496-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Since Huntingtin aggregates were undetectable by western blot assays using these vectors, we utilized an EGFP-fusion plasmid containing the exon 1 of HTT with 24 CAG repeats. HeLa cells were co-transfected with EGFP-Q24 and either the p97-PROTAC UBX-Nb<sup>(GFP)</sup> or an empty vector. The UBX system efficiently degraded Q24, as evidenced by a significant reduction in the levels of both monomeric protein and aggregates. Upon overexposure of the film, high-molecular-weight EGFP-Q24 species were detected. These bands were notably attenuated in cells treated with the UBX-Nb<sup>(GFP)</sup>, demonstrating that the p97-PROTAC effectively reduces the expression of Q24 and its aggregates (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), reinforcing the observations obtained by EGFP-Q23 and Q74.</p><p>To validate the versatility of the p97-PROTAC system, we generated an anti-α-synuclein p97-PROTAC by replacing the anti-GFP nanobody with a specific α-synuclein nanobody (NbSyn87) (<xref ref-type="bibr" rid="bib10">Butler et al., 2016</xref>; <xref ref-type="bibr" rid="bib21">El Turk et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">Chatterjee et al., 2018</xref>; <xref ref-type="bibr" rid="bib35">Guilliams et al., 2013</xref>). We tested the system using both GFP-tagged and untagged α-synuclein A53T mutant by co-transfecting cells with increasing concentrations of the p97-PROTAC UBX-Nb<sup>(Syn87)</sup> or an empty vector. In both cases, we observed efficient degradation of the α-synuclein A53T (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref>). As an additional measure to detect and quantify α-synuclein aggregation in our system, we performed aggregation assays using Thioflavin T (ThT), which is a small molecule that can bind specifically to β-sheet-rich structures of amyloid fibrils, enabling fluorescence-based detection. As shown in <xref ref-type="fig" rid="fig6">Figure 6E</xref>, aggregates were successfully detected in cells transfected with wild-type α-synuclein, and notably, the levels of these aggregates were reduced in cells that were co-transfected with p97-PROTAC UBX-Nb<sup>(Syn87)</sup> or with p97-PROTAC UBX-Nb<sup>(GFP)</sup>. Thus, we demonstrated that the nanobody component of the p97-PROTAC system is exchangeable, and the p97-PROTAC system is suitable for degrading human proteins of clinical interest.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Degradation of α-synuclein with p97-PROTAC.</title><p>(<bold>A</bold>) HeLa cells were co-transfected with a vector expressing αSynuclein mutant A53T fused to GFP (GFP-αSynuclein A53T) and empty or increasing concentrations of UBX-Nb<sup>(Syn87)</sup>. A53T-GFP degradation was determined by western blot. (<bold>B</bold>) Quantification of A, <italic>2 μg ‘p-value’ 0.0651 (ns), 4 μg ‘p-value’ 0.0020 (**</italic>). (<bold>C</bold>) Cells were co-transfected with a vector expressing untagged α-synuclein mutant A53T and an empty vector or increasing concentrations of UBX-Nb<sup>(Syn87)</sup>. Untagged αSynuclein A53T degradation was determined by western blot using an anti αSynuclein antibody. (<bold>D</bold>) Quantification of C, <italic>2 μg ‘p-value’ 0.0240 (*), 4 μg ‘p-value’ 0.0210 (*</italic>). (<bold>E</bold>) Quantification of α-synuclein aggregation via Thioflavin T (ThT) fluorescence. Non-transfected cells and cells transfected with GFP-tagged wild-type α-synuclein (pcDNA5 WT αSyn-GFP), either alone or co-transfected with the p97-based PROTACs containing nanobodies against GFP [UBX-Nb<sup>(GFP)</sup>] or α-synuclein [UBX-Nb<sup>(Syn87)</sup>], were analyzed for relative ThT fluorescence intensity normalized to total protein concentration (μg/μL). Bars represent mean ± SEM. Asterisks (*) indicate statistically significant differences compared to control (*p&lt;0.05, Dunnett’s post hoc test); ‘ns’ indicates no significant difference. (<bold>F</bold>) Representative model of p97-PROTAC functioning in the degradation of proteins and protein aggregates. Western blots were quantified and statistically analyzed using a Student’s t-test. p&lt;0.05 compared to controls. n=3.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw Western blots showing p97-PROTAC–mediated degradation of GFP-tagged and untagged α-synuclein A53T.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig6-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Annotated Western blots indicating protein bands for p97-PROTAC–mediated degradation of GFP-tagged and untagged α-synuclein A53T.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-101496-fig6-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101496-fig6-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The constitutive degradation of proteins is a rapid negative-regulatory mechanism, often involved in important stress response pathways. For example, under normoxia, Hif1α is rapidly hydroxylated in an oxygen-dependent manner, and the hydroxylation is recognized by an E3 ligase receptor called VHL leading to continuous ubiquitin-mediated proteasomal degradation (<xref ref-type="bibr" rid="bib63">Min et al., 2002</xref>; <xref ref-type="bibr" rid="bib57">McGettrick and O’Neill, 2020</xref>; <xref ref-type="bibr" rid="bib56">Masoud and Li, 2015</xref>; <xref ref-type="bibr" rid="bib96">Yeo, 2019</xref>). Hypoxia decreases Hif1α hydroxylation, and consequently, Hif1α dissociates from VHL, resulting in rapid stabilization, accumulation, and activation of the hypoxia response. Therefore, endogenous degradation is a natural and efficient way to downregulate the amount and function of proteins.</p><p>PROTAC technologies today rely on ubiquitin-mediated proteasomal degradation, but abnormal protein aggregation has multiple detrimental effects in the ubiquitin-mediated proteasomal degradation, including a significant reduction in the free ubiquitin pool and abundant ubiquitin accumulation in proteotoxic aggregates (<xref ref-type="bibr" rid="bib4">Ben Yehuda et al., 2017</xref>). Our p97-PROTAC technology provides a promising alternative to ubiquitin-mediated degradation, offering a novel approach to overcoming these challenges.</p><p>In this study, we demonstrated that an engineered p97-PROTAC consisting of a UBX domain fused to a camelid nanobody effectively induces specific protein degradation in cells. Using siRNA specific against the <italic>VCP</italic> gene, we abrogated substrate degradation, confirming the involvement of p97 in the process. Complementary to the siRNA assay, we utilized a p97-GFP vector, which further demonstrated that p97 contributes to the degradation of target proteins. These findings reinforce the central role of p97 in the functionality of the p97-PROTAC system.</p><p>In addition, we demonstrated that the degradation mechanism operates independently of ubiquitination, as shown by utilizing the ubiquitin E1 inhibitor PYR41. It is well established that different pools of the same protein can be directed to the proteasome via both ubiquitin-dependent and ubiquitin-independent mechanisms under the same cellular conditions (<xref ref-type="bibr" rid="bib43">Ju and Xie, 2004</xref>). Our findings are consistent with prior studies showing that various proteins can be degraded by the proteasome without ubiquitin tagging. Notably, intrinsically disordered regions or transiently unfolded states in proteins facilitate their recognition and degradation by the proteasome in a ubiquitin-independent manner (<xref ref-type="bibr" rid="bib10">Butler et al., 2016</xref>; <xref ref-type="bibr" rid="bib23">Erales and Coffino, 2014</xref>; <xref ref-type="bibr" rid="bib55">Makaros et al., 2023</xref>; <xref ref-type="bibr" rid="bib52">Li et al., 2025</xref>; <xref ref-type="bibr" rid="bib5">Bialek et al., 2023</xref>). In this context, p97’s ability to unfold substrates may play a critical role in exposing these unstructured regions, thereby enabling their recognition and processing by the proteasome.</p><p>Intriguingly, we observed that the activity of p97-PROTACs was not inhibited by the specific p97 ATPase inhibitor CB-5083. Thus, mechanistically, we cannot distinguish if the p97-PROTACs overcame the effect of the inhibitor or if the degradation mediated by the p97-PROTACs is mediated only by induced proximity to the proteasome and independent of p97’s ATPase activity. Although p97 has classically been described as a <italic>segregase</italic> that drives proteasomal degradation, it also plays critical roles in lysosomal and autophagic pathways (<xref ref-type="bibr" rid="bib62">Meyer et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Körner et al., 2025</xref>). This raises the possibility that substrate recruitment to p97 via our PROTAC system may activate additional degradation pathways. The observation that inhibition of the D2 domain by CB-5083 did not abolish degradation is consistent with this view and suggests either incomplete inhibition under our conditions or the involvement of other functions of p97, such as scaffolding properties or contributions from the D1 domain. Supporting this broader perspective, a 2021 study showed that gossypol, a clinically approved drug in China, reduces mHTT levels and improves motor function in Huntington’s disease models by stabilizing a VCP-LC3-mHTT ternary complex, thereby promoting autophagic clearance of mHTT (<xref ref-type="bibr" rid="bib51">Li et al., 2021</xref>). Moreover, ATP binding to the D1 domain influences adaptor selection, suggesting that D1 regulates cofactor engagement and may contribute to proteostasis through noncanonical mechanisms (<xref ref-type="bibr" rid="bib14">Chia et al., 2012</xref>). Together with recent structural insights into inter-domain communication within p97 (<xref ref-type="bibr" rid="bib81">Shein et al., 2024</xref>; <xref ref-type="bibr" rid="bib88">Turner et al., 2025</xref>), these findings support a model in which UBX adaptors can exploit both p97-dependent and partially independent mechanisms in a context-dependent manner. In our engineered PROTAC system, UBX recruitment enables degradation even under conditions where D2 activity is inhibited, consistent with a role for D1- or scaffold-mediated functions of p97. We therefore propose that UBX domains constitute a versatile platform capable of linking substrates either to canonical p97 <italic>unfoldase</italic> activity or to alternative degradation routes. Taken together, these results underscore the multifunctional nature of p97 and suggest that our technology may exploit not only the classical proteasomal pathway but also additional p97-dependent clearance mechanisms. However, further studies will be required to define the precise mechanisms by which p97-PROTACs mediate ubiquitin-independent degradation in cells.</p><p>p97 is an extensively characterized ubiquitously expressed protein involved in fundamental cellular processes, such as the degradation of proteins associated with the endoplasmic reticulum (ER) (ERAD) (<xref ref-type="bibr" rid="bib41">Hyun and Shin, 2021</xref>), autophagy (<xref ref-type="bibr" rid="bib17">Creekmore et al., 2024</xref>), and it is also an important player in the proteostasis of aggregates in Parkinson’s disease (<xref ref-type="bibr" rid="bib1">Alieva et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Merchant et al., 2019</xref>; <xref ref-type="bibr" rid="bib50">Lang and Espay, 2018</xref>). Indeed, p97 has been shown to protect against the proteopathic spread of pathogenic aggregates in animal models (<xref ref-type="bibr" rid="bib99">Zhu et al., 2021</xref>). In this study, we characterized p97 expression in the brains of animal models and observed ubiquitous p97 expression in all sections. Specifically, high p97 expression levels were detected in the cortex, SNpc, and hippocampus, regions highly prone to protein aggregation and neurodegeneration in neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease (<xref ref-type="bibr" rid="bib76">Ross and Poirier, 2004</xref>). These observations support the possibility of using p97-based PROTACs to reduce protein aggregation in neurodegeneration-related targets in the future.</p><p>The PROTAC technologies might increase the number of druggable proteins by a change in the inhibition paradigm. In contrast to conventional drugs that aim for chemical modulation of the enzymatic activity or function, PROTAC aims at the downregulation of the levels of specific targets based exclusively on selective binding and degradation.</p><p>In conclusion, our work unveils the potential of a p97-PROTAC as the first E3 ubiquitin ligase-independent technology that targets proteins for degradation at diverse subcellular locations, including integral membrane protein residing at the inner nuclear membrane, chromatin-located, and liquid-liquid phase-separated compartments. Also, it provides a new technology to target protein aggregates of clinical interest for proteasomal degradation. These findings establish p97-PROTAC as a versatile and promising platform for future therapeutic applications.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Design and cloning</title><p>The constructs were designed to include three main domains: an anti-GFP nanobody (<xref ref-type="bibr" rid="bib26">Fulcher et al., 2016</xref>), which specifically binds to the target protein; a linker and the UBX domain of the p97 adaptor FAF1. The linker used to connect both domains (KESGSVSSEQLAQFRSLD) was originally designed for the construction of single-chain antigen-binding proteins, providing sufficient flexibility to connect the domains without hindering the antigen-binding capacity (<xref ref-type="bibr" rid="bib6">Bird et al., 1988</xref>). The anti-GFP nanobody is capable of recognizing both YFP and GFP proteins. Additionally, a myc-tag was incorporated to confirm expression. The full sequence was cloned into the pcDNA 5 FRT/TO vector by the Gibson Assembly technique. Later, the anti-GFP nanobody was replaced with an anti-α-synuclein nanobody (NbSyn87) using restriction enzymes (<xref ref-type="bibr" rid="bib10">Butler et al., 2016</xref>; <xref ref-type="bibr" rid="bib21">El Turk et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">Chatterjee et al., 2018</xref>; <xref ref-type="bibr" rid="bib35">Guilliams et al., 2013</xref>). Furthermore, the UBX domain was removed by restriction enzyme digestion, resulting in the Nb-anti-GFP-Myc-tag vector.</p></sec><sec id="s4-2"><title>Cell culture</title><p>HeLa and U2OS cells were generously provided by Professor Ronald T. Hay (University of Dundee). Authentication certificates were not available; however, the morphology and growth characteristics of both lines were consistent with those expected for HeLa and U2OS cells. Cultures were routinely screened and tested negative for mycoplasma contamination. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented with 10% fetal bovine serum and 100 units/mL penicillin–streptomycin and maintained at 37°C in a humidified incubator with 5% CO₂. Plasmid transfection was performed in six-well plates using 4 μg of DNA, 24 hr after transfection, cells were lysed, and proteins were collected. Cells were transiently transfected with the following vectors: pcDNA5 FRT/TO GFP-ETV1, pcDNA5 FRT/TO GFP-Emerin, pEYFP-Coilin, pcDNA FRT/TO GFP, VCP(wt)-EGFP (Addgene, #23971), pEGFP-C1-tagged plasmids containing the exon 1 of HTT with 23 CAG repeats (pEGFP-Q23: wild-type HTT, Addgene, #40261) or 74 CAG repeats (pEGFP-Q74: mutant HTT, Addgene, #40262) and pEGFP-Q24 (generously provided by Dr. Maite Castro, Universidad Austral de Chile). Vectors to α-synuclein were a gift from our collaborator Dr. Gopal Sapkota (pcDNA5-FRT/TO-GFP-SCNA-A53T, #59047 or pcDNA5-FRT/TO-SCNA-A53T, #59042). As a control, we used an empty vector pcDNA5 FRT/TO. Transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions, and media were supplemented with normocin (100 µg/mL) during transfection (Invivogen). For lysis, cells were washed twice in ice-cold phosphate-buffered saline (PBS), scraped on ice in lysis buffer (Tris-HCl pH 6.8, NaCl, glycerol, and SDS 10%), supplemented with complete protease inhibitors (one tablet per 25 mL: Roche), and 0.1% β-mercaptoethanol (Sigma). Cell extracts were either cleared and processed immediately or stored at –20°C. The protein concentration was determined in a 96-well format using the Pierce BCA protein assay kit (Thermo Fisher Scientific).</p></sec><sec id="s4-3"><title>Antibodies and inhibitors</title><p>We used the following primary antibodies: anti-GFP (Invitrogen, GF28R mAb MA5-15256), anti-α-synuclein (Santa Cruz Biotechnology, 3H2897 mAb sc-69977), anti-53BP1 (Invitrogen, 53BP1 Polyclonal Antibody PA1-16565), anti-Myc-tag (Cell Signaling, 9B11 Mouse mAb #2276), anti-vcp/p97 (Sigma-Aldrich Polyclonal Antibody HPA012728), anti-p53 (Invitrogen, monoclonal antibody DO-7 #MA5-12557), anti-CHOP (Cell Signaling, L63F7 Mouse mAb #2895), anti-ubiquitin (Sigma-Aldrich ST1200 Mouse mAb FK2), anti-α-tubulin (Santa Cruz Biotechnology, B7 mAb sc-5286), anti-GAPDH (Santa Cruz Biotechnology, mAb sc-47724), anti-vinculin (Santa Cruz Biotechnology, 7F9 mAb sc-73614). Horseradish peroxidase (HRP)-coupled secondary antibodies and Alexa Fluor secondary antibodies were purchased from Invitrogen (Thermo Fisher): Mouse IgG, IgM (H+L) Secondary Antibody (A-10677), Rabbit IgG (H+L) Secondary Antibody (31460), and Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody (A-11032).</p><p>The inhibitors used in this work were: MG132, a proteasome inhibitor from Sigma-Aldrich (catalog number 474790); PYR-41, an E1 ligase inhibitor from Sigma-Aldrich (catalog number N2915); and CB-5085, a D2 domain inhibitor of p97 from Cayman Chemical.</p></sec><sec id="s4-4"><title>Generation of a 53BP1 endogenously tagged YFP-53BP1 using CRISPR/Cas9</title><p>U2OS T-Rex cells were co-transfected with the pOG44 plasmid, which constitutively expresses the Flp recombinase and pcDNA5 FRT/TO codon optimized <italic>Streptococcus pyogenes</italic> M1 GAS Cas9 D10A-NLS-FLAG (DU45732 MRC-PPU reagent) for isogenic integration of the cassette. To decrease possible off-target effects, we applied the Cas9 D10A nickase system for genetic cleavage. Single clones were selected to generate the U2OS stable expressing Cas9 D10A cells, U2OS SEC-C D10A. Two specific guide RNAs (gRNAs) targeting sequences were identified in the 5' UTR before the 53BP1 start codon using the E-CRISPR software (<ext-link ext-link-type="uri" xlink:href="http://www.e-crisp.org/E-CRISP/reannotate_crispr.html">http://www.e-crisp.org/E-CRISP/reannotate_crispr.html</ext-link>). The forward gRNA g53BP1-1 5'<named-content content-type="sequence">AGACCTCTAGCTCGAGCGCGAGG</named-content> 3' and a reverse gRNA g53BP1-7 5'<named-content content-type="sequence">GTCCCTCCAGATCGATCCCTAGG</named-content> 3' were cloned into pU6-Puro via site-directed mutagenesis using the QuickChange method (Stratagene) cloned using the previously described methodology and confirmed by DNA sequencing (<xref ref-type="bibr" rid="bib75">Rojas-Fernandez et al., 2015</xref>; <xref ref-type="bibr" rid="bib67">Munoz et al., 2014</xref>). We designed a strategy for YFP delivery at the N-terminus of the 53BP1 protein using a CRISPR/Cas9 KI methodology. In short, the sense and antisense gRNAs were transfected in U2OS T-Rex cells and modified to produce Cas9 D10A nickase in a doxycycline-inducible manner. We also engineered a synthetic vector with two homologous flanking regions around the cleavage site, where we inserted YFP cDNA and small linker in front of the endogenous 53BP1 gene synthetically produced by GeneArt (Life Technologies). The gRNA recognition sites were mutated on the synthetic donor to avoid cleavage by the gRNA/Cas9 complex. Finally, the two gRNAs and the donor vector carrying the YFP cDNA flanked with the homologue regions were transfected in U2OS cells. The day after the cells were transfected, the expression of the Cas9 nuclease was induced by adding 1 µg/mL doxycycline, and the cells were incubated for 4 days before FACS analysis to identify YFP-positive cells and further cell sorting based on single-cell isolation.</p></sec><sec id="s4-5"><title>Flow cytometry and cell sorting</title><p>Cells were analyzed for YFP fluorescence on an LSR Fortessa or FACS Canto flow cytometer (Becton Dickinson), and data were analyzed using FlowJo software (Tree Star Inc). Single cells were identified based on FSC-A, FSC-W, and SSC-A, and YFP fluorescence measured with 488 nm excitation and emission detected at 530±30 nm. Cell sorting was performed on an Influx cell sorter (Becton Dickinson) with FACS software, using the same cell identification procedure described above. Single YFP-expressing cells were sorted onto individual wells of a 96-well plate containing DMEM supplemented with 20% fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, and 100 µg/mL transfection-compatible antibiotic normocin 1× (Invivogene). Single-cell clones were left to proliferate, and YFP fluorescence was determined.</p></sec><sec id="s4-6"><title>Immunofluorescence and high-content microscopy</title><p>HeLa cells transfected with GFP proteins were grown in a 96-well optical plate (Thermo Fisher Scientific) or 24-well lidded plates. Cells were fixed with 4% paraformaldehyde at 37°C for 10 min. Cells were washed with 1× PBS and permeabilized in 0.2% Triton X-100 PBS. After washing the cells three times in 1× PBS, they were incubated with blocking solution (FBS 5%-PBS 1×) for 30 min and then incubated with the primary antibody for 1 hr at 37°C. After washing another three times with 1× PBS, a secondary antibody Alexa Fluor was used at 1: 3000, it was incubated for 45 min at 37°C. For nuclei staining, cells were washed with PBS and incubated for 10 min at room temperature with 0.1 mg/mL DAPI. After the final wash, the cells were kept in the 96-well optical plates in 1× PBS. Cover-fixed cells were mounted on slides. Fixed cell images were acquired with a high-content automated microscope, CellDiscoverer 7 (Carl Zeiss GmbH, Jena, Germany).</p></sec><sec id="s4-7"><title>Silencing assay</title><p>HeLa cells were cultured in a six-well plate and transfected with siRNAs control siRNA-B, (sc-44230), or <italic>VCP</italic> siRNA (sc-37187) at 40% confluence. Transfection was performed using Lipofectamine RNAiMax (Invitrogen) according to the manufacturer’s instructions, and the media were supplemented with Normocin (Invivogen) during transfection. Twenty-four hours post-siRNA transfection, the medium was changed to fresh DMEM-Normocin, and GFP-Emerin, as well as both the empty vector and the UBX-Nb<sup>(GFP)</sup> vector, was co-transfected. The complexes were left in culture for 48 hr. Subsequently, total proteins were extracted with lysis buffer to perform the western blot assay.</p></sec><sec id="s4-8"><title>ThT fluorescence measurement protocol</title><p>Fluorescence measurements were performed using a FluoroStar Omega microplate reader (BMG Labtech, Germany) and a 96-well SPL Black plate (SPL Life Sciences, Korea). Each reaction well contained a final volume of 100 µL, consisting of 15 µL of cell culture, Thioflavin T (ThT, Sigma-Aldrich) at a final concentration of 15 µM, and PBS pH 7 (Gibco, Thermo Fisher Scientific). Prior to measurement, samples were homogenized by double orbital shaking at 300 rpm for 60 s. The fluorescence intensity mode was used, with spiral averaging and a scan diameter of 10 mm. A single read cycle was performed with 100 flashes per well to enhance measurement accuracy. Optical settings were configured with an excitation wavelength of 448±10 nm and an emission wavelength of 482±10 nm. Fluorescence values were normalized to total protein concentration, determined using the BCA assay (Biovision, USA), and relative ThT fluorescence was expressed as a function of protein concentration (µg/µL).</p></sec><sec id="s4-9"><title>SDS-PAGE and western blotting</title><p>Reduced protein extracts were separated on 10% SDS-PAGE gels or 4–12% NuPAGE Bis–Tris precast gels (Invitrogen) by electrophoresis. Proteins were then transferred onto nitrocellulose membranes (Millipore). Nonspecific sites were blocked with blocking solution (PBS containing 0.1% Tween 20 with 5% [wt/vol] nonfat milk) for 30 min at room temperature with agitation. The blocking solution was discarded, and membranes were incubated overnight at 4°C in 5% BSA PBS-T (PBS 1× containing 0.1% Tween 20) with the appropriate primary antibodies. Membranes were then washed in PBS-T and incubated with HRP-conjugated secondary antibodies in 5% milk-PBS-T for 1 hr at room temperature, followed by 3×5 min washes with PBS-T and visualized using the ECL reagent (Pierce) and exposure on medical X-ray films.</p></sec><sec id="s4-10"><title>Animals, fixation, and tissue processing</title><p>Mouse (C57BL6/C mice), rat (Sprague-Dawley), and monkey (<italic>M. fascicularis</italic>) brain sections were obtained from the brain bank of HM CINAC. All procedures with animals were carried out in accordance with the Directive of the Council of the European Communities (2010/63/EU) and Spanish legislation (RD53/2013) on animal experimentation. Animal perfusion, fixation, and tissue processing were carried out as previously described (<xref ref-type="bibr" rid="bib18">Del Rey et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Del Rey et al., 2022</xref>).</p></sec><sec id="s4-11"><title>Brain immunohistochemistry</title><p>Coronal free-floating 30-mm-thick sections were washed with Tris buffer and treated with citrate buffer (pH 6) for 30 min at 37°C for antigen retrieval. Inhibition of endogenous peroxidase activity was carried out using a mixture of 10% methanol and 3% concentrated H<sub>2</sub>O<sub>2</sub> for 20 min at room temperature. Normal serum of the same species as the secondary antibody (Normal Goat Serum [NGS]) was applied for 3 hr to block nonspecific binding sites. The sections were immunostained with anti-p97 antibody (Rabbit polyclonal anti-vcp, Sigma-Aldrich HPA012728, dilution 1: 1000) at 4°C for 72 hr. The sections were washed with Tris-buffered saline (TBS) and incubated for 2 hr with a solution containing the secondary biotinylated antibody (goat anti-rabbit, dilution 1:400; Chemicon, Burlington, MA, USA) in TBS-NGS. The sections were then incubated for 45 min with the avidin-biotin-peroxidase complex (PK-6100, ABC Vectastain; Vector Laboratories, Burlingame, CA, USA). Immunohistochemical reactions were visualized by incubating the sections with 0.05% 3,3-diaminobenzidine (DAB, Sigma, St. Louis, MO, USA) and 0.003% H<sub>2</sub>O<sub>2</sub>. The sections were then dehydrated with graduated ethyl alcohol (EtOH) and rinsed in two xylene changes before being mounted in dibutyl polystyrene xylene phthalate (DPX) and applying glass coverslips. Omission of the primary antibody resulted in a lack of staining (images not shown).</p></sec><sec id="s4-12"><title>Molecular modeling</title><p>An atomic model of UBX-Nb<sup>(GFP)</sup> was predicted using the AlphaFold2 algorithm via the ColabFold notebook (<xref ref-type="bibr" rid="bib64">Mirdita et al., 2021</xref>; <xref ref-type="bibr" rid="bib44">Jumper et al., 2021</xref>). The FAF1 UBX domain position on the p97 hexamer was modeled by LSQ superposition of the p97 N-domain portion of a p97-N/FAF1 UBX co-crystal structure (PDB 3qq8) with the N-domain of chain A of a p97 hexamer cryo-EM structure (PDB 7jy5) using the program Coot (<xref ref-type="bibr" rid="bib36">Hänzelmann et al., 2011</xref>; <xref ref-type="bibr" rid="bib72">Pan et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Emsley et al., 2010</xref>). Subsequently, the FAF1 UBX domain portion of the AlphaFold prediction was aligned with the p97/FAF1 UBX domain model using LSQ superpose in Coot. The conformation of the flexible linker between Nb<sup>(GFP)</sup> and FAF1 UBX domain in the fusion protein model was manually adjusted using the ‘Regularize Zone’ feature in Coot. Finally, the position of GFP was modeled by LSQ superposition of the nanobody portion of the adjusted UBX-Nb<sup>(GFP)</sup> coordinates with the crystal structure of a Nb<sup>(GFP)</sup>/GFP co-crystal structure (PDB 3ogo).</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>The results are presented as the mean ± SEM. All statistical analyses were performed using the GraphPad Prism software. For all western blots, an unpaired Student’s t-test was performed to determine differences between control cells transfected with an empty vector versus UBX-Nb<sup>(GFP or Syn87)</sup>-treated cells. A confidence level of 95% (p&lt;0.05) was accepted as statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>Is an investor of the patent request WO2023187761A1</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Formal analysis, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Supervision, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Data curation, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-101496-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated in this study are included in the manuscript and supporting files. Source data files for all gels and blots are provided for each main and figure supplement, including original unprocessed images and labeled versions.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was funded by ANID MPG190011 to ARF; FONDECYT REGULAR 1200427 to ARF; FONIS EU-LAC T010047 to CSR, PCC, JO, JB, NLR, and ARF; to ARF; ANID-EXPLORACIÓN 13220075 to ARF and GVN; ANID 3220635 to GVN; MPG 190011 to ARF; Centro Ciencia and Vida, FB210008, Financiamiento Basal para Centros Científicos y Tecnológicos de Excelencia de ANID to ARF; ANID-STINT CS2018-7952. JB was funded by ISCIII Miguel Servet Program CP19/00200 and FIS PI20/00496. Graduate fellowship ANID N° 22170632 to CS; NLGR was funded by Becas Santander Iberoamerica Investigacion 2018/2019 and grant S2017/BMD-3700 (NEUROMETAB-CM) from Comunidad de Madrid; DS was supported by the German Research Foundation (DFG) Emmy Noether Programme SCHW1851/1-1. We would like to thank Anne Berking and Amber Philp for proofreading and Felipe Serrano for illustration.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alieva</surname><given-names>A</given-names></name><name><surname>Rudenok</surname><given-names>M</given-names></name><name><surname>Filatova</surname><given-names>E</given-names></name><name><surname>Karabanov</surname><given-names>A</given-names></name><name><surname>Doronina</surname><given-names>O</given-names></name><name><surname>Doronina</surname><given-names>K</given-names></name><name><surname>Kolacheva</surname><given-names>A</given-names></name><name><surname>Ugrumov</surname><given-names>M</given-names></name><name><surname>Illarioshkin</surname><given-names>S</given-names></name><name><surname>Slominsky</surname><given-names>P</given-names></name><name><surname>Shadrina</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson’s disease</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>827</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-57938-3</pub-id><pub-id pub-id-type="pmid">31964996</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alnot</surname><given-names>JY</given-names></name><name><surname>Frajman</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Chronic ulnar nerve compression syndrome at the elbow apropos of 74 cases</article-title><source>Annales de Chirurgie de La Main et Du Membre Superieur</source><volume>11</volume><fpage>5</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/s0753-9053(05)80046-8</pub-id><pub-id pub-id-type="pmid">1375494</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Békés</surname><given-names>M</given-names></name><name><surname>Langley</surname><given-names>DR</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>PROTAC targeted protein degraders: the past is prologue</article-title><source>Nature Reviews. Drug Discovery</source><volume>21</volume><fpage>181</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00371-6</pub-id><pub-id pub-id-type="pmid">35042991</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Yehuda</surname><given-names>A</given-names></name><name><surname>Risheq</surname><given-names>M</given-names></name><name><surname>Novoplansky</surname><given-names>O</given-names></name><name><surname>Bersuker</surname><given-names>K</given-names></name><name><surname>Kopito</surname><given-names>RR</given-names></name><name><surname>Goldberg</surname><given-names>M</given-names></name><name><surname>Brandeis</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ubiquitin accumulation on disease associated protein aggregates is correlated with nuclear ubiquitin depletion, histone de-ubiquitination and impaired DNA damage response</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0169054</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0169054</pub-id><pub-id pub-id-type="pmid">28052107</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bialek</surname><given-names>W</given-names></name><name><surname>Collawn</surname><given-names>JF</given-names></name><name><surname>Bartoszewski</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Ubiquitin-dependent and independent proteasomal degradation in host-pathogen interactions</article-title><source>Molecules</source><volume>28</volume><elocation-id>6740</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28186740</pub-id><pub-id pub-id-type="pmid">37764516</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>RE</given-names></name><name><surname>Hardman</surname><given-names>KD</given-names></name><name><surname>Jacobson</surname><given-names>JW</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Kaufman</surname><given-names>BM</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Pope</surname><given-names>SH</given-names></name><name><surname>Riordan</surname><given-names>GS</given-names></name><name><surname>Whitlow</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Single-chain antigen-binding proteins</article-title><source>Science</source><volume>242</volume><fpage>423</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1126/science.3140379</pub-id><pub-id pub-id-type="pmid">3140379</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blesa</surname><given-names>J</given-names></name><name><surname>Foffani</surname><given-names>G</given-names></name><name><surname>Dehay</surname><given-names>B</given-names></name><name><surname>Bezard</surname><given-names>E</given-names></name><name><surname>Obeso</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?</article-title><source>Nature Reviews. Neuroscience</source><volume>23</volume><fpage>115</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/s41583-021-00542-9</pub-id><pub-id pub-id-type="pmid">34907352</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodnar</surname><given-names>NO</given-names></name><name><surname>Rapoport</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Molecular mechanism of substrate processing by the Cdc48 ATPase complex</article-title><source>Cell</source><volume>169</volume><fpage>722</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.04.020</pub-id><pub-id pub-id-type="pmid">28475898</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bondeson</surname><given-names>DP</given-names></name><name><surname>Mares</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>IED</given-names></name><name><surname>Ko</surname><given-names>E</given-names></name><name><surname>Campos</surname><given-names>S</given-names></name><name><surname>Miah</surname><given-names>AH</given-names></name><name><surname>Mulholland</surname><given-names>KE</given-names></name><name><surname>Routly</surname><given-names>N</given-names></name><name><surname>Buckley</surname><given-names>DL</given-names></name><name><surname>Gustafson</surname><given-names>JL</given-names></name><name><surname>Zinn</surname><given-names>N</given-names></name><name><surname>Grandi</surname><given-names>P</given-names></name><name><surname>Shimamura</surname><given-names>S</given-names></name><name><surname>Bergamini</surname><given-names>G</given-names></name><name><surname>Faelth-Savitski</surname><given-names>M</given-names></name><name><surname>Bantscheff</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Gordon</surname><given-names>DA</given-names></name><name><surname>Willard</surname><given-names>RR</given-names></name><name><surname>Flanagan</surname><given-names>JJ</given-names></name><name><surname>Casillas</surname><given-names>LN</given-names></name><name><surname>Votta</surname><given-names>BJ</given-names></name><name><surname>den Besten</surname><given-names>W</given-names></name><name><surname>Famm</surname><given-names>K</given-names></name><name><surname>Kruidenier</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>PS</given-names></name><name><surname>Harling</surname><given-names>JD</given-names></name><name><surname>Churcher</surname><given-names>I</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Catalytic in vivo protein knockdown by small-molecule PROTACs</article-title><source>Nature Chemical Biology</source><volume>11</volume><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1858</pub-id><pub-id pub-id-type="pmid">26075522</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>DC</given-names></name><name><surname>Joshi</surname><given-names>SN</given-names></name><name><surname>Genst</surname><given-names>ED</given-names></name><name><surname>Baghel</surname><given-names>AS</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Messer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bifunctional anti-non-amyloid component α-synuclein nanobodies are protective in situ</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0165964</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0165964</pub-id><pub-id pub-id-type="pmid">27824888</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffrey</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Berezuk</surname><given-names>A</given-names></name><name><surname>Tuttle</surname><given-names>K</given-names></name><name><surname>Chittori</surname><given-names>S</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>AAA+ ATPase p97/VCP mutants and inhibitor binding disrupt inter-domain coupling and subsequent allosteric activation</article-title><source>The Journal of Biological Chemistry</source><volume>297</volume><elocation-id>101187</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.101187</pub-id><pub-id pub-id-type="pmid">34520757</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caussinus</surname><given-names>E</given-names></name><name><surname>Kanca</surname><given-names>O</given-names></name><name><surname>Affolter</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fluorescent fusion protein knockout mediated by anti-GFP nanobody</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>19</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2180</pub-id><pub-id pub-id-type="pmid">22157958</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>D</given-names></name><name><surname>Bhatt</surname><given-names>M</given-names></name><name><surname>Butler</surname><given-names>D</given-names></name><name><surname>De Genst</surname><given-names>E</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Messer</surname><given-names>A</given-names></name><name><surname>Kordower</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model</article-title><source>NPJ Parkinson’s Disease</source><volume>4</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1038/s41531-018-0062-4</pub-id><pub-id pub-id-type="pmid">30155513</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname><given-names>WS</given-names></name><name><surname>Chia</surname><given-names>DX</given-names></name><name><surname>Rao</surname><given-names>F</given-names></name><name><surname>Bar Nun</surname><given-names>S</given-names></name><name><surname>Geifman Shochat</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ATP Binding to p97/VCP D1 domain regulates selective recruitment of adaptors to its proximal N-Domain</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e50490</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0050490</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciechanover</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The ubiquitin-proteasome proteolytic pathway</article-title><source>Cell</source><volume>79</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90396-4</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clift</surname><given-names>D</given-names></name><name><surname>So</surname><given-names>C</given-names></name><name><surname>McEwan</surname><given-names>WA</given-names></name><name><surname>James</surname><given-names>LC</given-names></name><name><surname>Schuh</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Acute and rapid degradation of endogenous proteins by Trim-Away</article-title><source>Nature Protocols</source><volume>13</volume><fpage>2149</fpage><lpage>2175</lpage><pub-id pub-id-type="doi">10.1038/s41596-018-0028-3</pub-id><pub-id pub-id-type="pmid">30250286</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creekmore</surname><given-names>BC</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Neurodegenerative disease tauopathies</article-title><source>Annual Review of Pathology</source><volume>19</volume><fpage>345</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-051222-120750</pub-id><pub-id pub-id-type="pmid">37832941</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Rey</surname><given-names>NL-G</given-names></name><name><surname>Balzano</surname><given-names>T</given-names></name><name><surname>Martin-Rodriguez</surname><given-names>L</given-names></name><name><surname>Salinas-Rebolledo</surname><given-names>C</given-names></name><name><surname>Trigo-Damas</surname><given-names>I</given-names></name><name><surname>Rojas-Fernandez</surname><given-names>A</given-names></name><name><surname>Alvarez-Erviti</surname><given-names>L</given-names></name><name><surname>Blesa</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Lack of parkinsonian pathology and neurodegeneration in mice after long-term injections of a proteasome inhibitor in olfactory bulb and amygdala</article-title><source>Frontiers in Aging Neuroscience</source><volume>13</volume><elocation-id>698979</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2021.698979</pub-id><pub-id pub-id-type="pmid">34744683</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Rey</surname><given-names>NL-G</given-names></name><name><surname>Trigo-Damas</surname><given-names>I</given-names></name><name><surname>Obeso</surname><given-names>JA</given-names></name><name><surname>Cavada</surname><given-names>C</given-names></name><name><surname>Blesa</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Neuron types in the primate striatum: Stereological analysis of projection neurons and interneurons in control and parkinsonian monkeys</article-title><source>Neuropathology and Applied Neurobiology</source><volume>48</volume><elocation-id>e12812</elocation-id><pub-id pub-id-type="doi">10.1111/nan.12812</pub-id><pub-id pub-id-type="pmid">35274336</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>KM</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Ching</surname><given-names>KA</given-names></name><name><surname>Batalov</surname><given-names>S</given-names></name><name><surname>Tsai</surname><given-names>C-C</given-names></name><name><surname>Joazeiro</surname><given-names>CAP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates</article-title><source>PNAS</source><volume>100</volume><fpage>8892</fpage><lpage>8897</lpage><pub-id pub-id-type="doi">10.1073/pnas.1530212100</pub-id><pub-id pub-id-type="pmid">12857950</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Turk</surname><given-names>F</given-names></name><name><surname>De Genst</surname><given-names>E</given-names></name><name><surname>Guilliams</surname><given-names>T</given-names></name><name><surname>Fauvet</surname><given-names>B</given-names></name><name><surname>Hejjaoui</surname><given-names>M</given-names></name><name><surname>Di Trani</surname><given-names>J</given-names></name><name><surname>Chiki</surname><given-names>A</given-names></name><name><surname>Mittermaier</surname><given-names>A</given-names></name><name><surname>Vendruscolo</surname><given-names>M</given-names></name><name><surname>Lashuel</surname><given-names>HA</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Exploring the role of post-translational modifications in regulating α-synuclein interactions by studying the effects of phosphorylation on nanobody binding</article-title><source>Protein Science</source><volume>27</volume><fpage>1262</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1002/pro.3412</pub-id><pub-id pub-id-type="pmid">29603451</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of Coot</article-title><source>Acta Crystallogr D Biol Crystallogr. Apr</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erales</surname><given-names>J</given-names></name><name><surname>Coffino</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ubiquitin-independent proteasomal degradation</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1843</volume><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2013.05.008</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falcão de Campos</surname><given-names>C</given-names></name><name><surname>de Carvalho</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Distal myopathy and rapidly progressive dementia associated with a novel mutation in the VCP gene: Expanding inclusion body myopathy with early-onset Paget disease and frontotemporal dementia spectrum</article-title><source>Journal of Clinical Neuroscience</source><volume>64</volume><fpage>8</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2019.03.063</pub-id><pub-id pub-id-type="pmid">30955949</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández-Sáiz</surname><given-names>V</given-names></name><name><surname>Buchberger</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Imbalances in p97 co-factor interactions in human proteinopathy</article-title><source>EMBO Reports</source><volume>11</volume><fpage>479</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/embor.2010.49</pub-id><pub-id pub-id-type="pmid">20414249</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulcher</surname><given-names>LJ</given-names></name><name><surname>Macartney</surname><given-names>T</given-names></name><name><surname>Bozatzi</surname><given-names>P</given-names></name><name><surname>Hornberger</surname><given-names>A</given-names></name><name><surname>Rojas-Fernandez</surname><given-names>A</given-names></name><name><surname>Sapkota</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An affinity-directed protein missile system for targeted proteolysis</article-title><source>Open Biology</source><volume>6</volume><elocation-id>160255</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.160255</pub-id><pub-id pub-id-type="pmid">27784791</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulcher</surname><given-names>LJ</given-names></name><name><surname>Hutchinson</surname><given-names>LD</given-names></name><name><surname>Macartney</surname><given-names>TJ</given-names></name><name><surname>Turnbull</surname><given-names>C</given-names></name><name><surname>Sapkota</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting endogenous proteins for degradation through the affinity-directed protein missile system</article-title><source>Open Biology</source><volume>7</volume><elocation-id>170066</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.170066</pub-id><pub-id pub-id-type="pmid">28490657</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Yuan</surname><given-names>HX</given-names></name><name><surname>Li</surname><given-names>XQ</given-names></name><name><surname>Power</surname><given-names>JT</given-names></name><name><surname>Blumbergs</surname><given-names>PC</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies</article-title><source>Experimental Neurology</source><volume>166</volume><fpage>324</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1006/exnr.2000.7527</pub-id><pub-id pub-id-type="pmid">11085897</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galindo-Moreno</surname><given-names>M</given-names></name><name><surname>Giráldez</surname><given-names>S</given-names></name><name><surname>Sáez</surname><given-names>C</given-names></name><name><surname>Japón</surname><given-names>MÁ</given-names></name><name><surname>Tortolero</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Both p62/SQSTM1-HDAC6-dependent autophagy and the aggresome pathway mediate CDK1 degradation in human breast cancer</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>10078</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-10506-8</pub-id><pub-id pub-id-type="pmid">28855742</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galves</surname><given-names>M</given-names></name><name><surname>Rathi</surname><given-names>R</given-names></name><name><surname>Prag</surname><given-names>G</given-names></name><name><surname>Ashkenazi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ubiquitin signaling and degradation of aggregate-prone proteins</article-title><source>Trends in Biochemical Sciences</source><volume>44</volume><fpage>872</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2019.04.007</pub-id><pub-id pub-id-type="pmid">31079890</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>DK</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Ranjan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The ATPase VCP/p97 functions as a disaggregase against toxic Huntingtin-exon1 aggregates</article-title><source>FEBS Letters</source><volume>592</volume><fpage>2680</fpage><lpage>2692</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.13213</pub-id><pub-id pub-id-type="pmid">30069866</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gómez-Isla</surname><given-names>T</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes</article-title><source>Nature Reviews. Neurology</source><volume>18</volume><fpage>323</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/s41582-022-00642-9</pub-id><pub-id pub-id-type="pmid">35332316</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>MA</given-names></name><name><surname>Feely</surname><given-names>SM</given-names></name><name><surname>Speziani</surname><given-names>F</given-names></name><name><surname>Strickland</surname><given-names>AV</given-names></name><name><surname>Danzi</surname><given-names>M</given-names></name><name><surname>Bacon</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Chou</surname><given-names>T-F</given-names></name><name><surname>Blanton</surname><given-names>SH</given-names></name><name><surname>Weihl</surname><given-names>CC</given-names></name><name><surname>Zuchner</surname><given-names>S</given-names></name><name><surname>Shy</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A novel mutation in VCP causes charcot–marie–tooth type 2 disease</article-title><source>Brain</source><volume>137</volume><fpage>2897</fpage><lpage>2902</lpage><pub-id pub-id-type="doi">10.1093/brain/awu224</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Pérez</surname><given-names>P</given-names></name><name><surname>Cirulli</surname><given-names>ET</given-names></name><name><surname>Drory</surname><given-names>VE</given-names></name><name><surname>Dabby</surname><given-names>R</given-names></name><name><surname>Nisipeanu</surname><given-names>P</given-names></name><name><surname>Carasso</surname><given-names>RL</given-names></name><name><surname>Sadeh</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>A</given-names></name><name><surname>Festoff</surname><given-names>BW</given-names></name><name><surname>Sapp</surname><given-names>PC</given-names></name><name><surname>McKenna-Yasek</surname><given-names>D</given-names></name><name><surname>Goldstein</surname><given-names>DB</given-names></name><name><surname>Brown</surname><given-names>RH</given-names><suffix>Jr</suffix></name><name><surname>Blumen</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Novel mutation in <italic>VCP</italic> gene causes atypical amyotrophic lateral sclerosis</article-title><source>Neurology</source><volume>79</volume><fpage>2201</fpage><lpage>2208</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318275963b</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilliams</surname><given-names>T</given-names></name><name><surname>El-Turk</surname><given-names>F</given-names></name><name><surname>Buell</surname><given-names>AK</given-names></name><name><surname>O’Day</surname><given-names>EM</given-names></name><name><surname>Aprile</surname><given-names>FA</given-names></name><name><surname>Esbjörner</surname><given-names>EK</given-names></name><name><surname>Vendruscolo</surname><given-names>M</given-names></name><name><surname>Cremades</surname><given-names>N</given-names></name><name><surname>Pardon</surname><given-names>E</given-names></name><name><surname>Wyns</surname><given-names>L</given-names></name><name><surname>Welland</surname><given-names>ME</given-names></name><name><surname>Steyaert</surname><given-names>J</given-names></name><name><surname>Christodoulou</surname><given-names>J</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>De Genst</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stages</article-title><source>Journal of Molecular Biology</source><volume>425</volume><fpage>2397</fpage><lpage>2411</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2013.01.040</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hänzelmann</surname><given-names>P</given-names></name><name><surname>Buchberger</surname><given-names>A</given-names></name><name><surname>Schindelin</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hierarchical binding of cofactors to the AAA ATPase p97</article-title><source>Structure</source><volume>19</volume><fpage>833</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1016/j.str.2011.03.018</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirabayashi</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Nakadate</surname><given-names>K</given-names></name><name><surname>Ohsawa</surname><given-names>Y</given-names></name><name><surname>Kamei</surname><given-names>Y</given-names></name><name><surname>Popiel</surname><given-names>AH</given-names></name><name><surname>Sinohara</surname><given-names>A</given-names></name><name><surname>Iwamatsu</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Kakizuka</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration</article-title><source>Cell Death and Differentiation</source><volume>8</volume><fpage>977</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4400907</pub-id><pub-id pub-id-type="pmid">11598795</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>AJ</given-names></name><name><surname>Fachinetti</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>JS</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inducible, reversible system for the rapid and complete degradation of proteins in mammalian cells</article-title><source>PNAS</source><volume>109</volume><fpage>E3350</fpage><lpage>E3357</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216880109</pub-id><pub-id pub-id-type="pmid">23150568</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z-R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RNF126-mediated reubiquitination is required for proteasomal degradation of p97-extracted membrane proteins</article-title><source>Molecular Cell</source><volume>79</volume><fpage>320</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.06.023</pub-id><pub-id pub-id-type="pmid">32645369</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Figueiredo-Pereira</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications</article-title><source>Apoptosis</source><volume>15</volume><fpage>1292</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1007/s10495-010-0466-z</pub-id><pub-id pub-id-type="pmid">20131003</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyun</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Chemical-mediated targeted protein degradation in neurodegenerative diseases</article-title><source>Life</source><volume>11</volume><elocation-id>607</elocation-id><pub-id pub-id-type="doi">10.3390/life11070607</pub-id><pub-id pub-id-type="pmid">34202541</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>AFM</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Tatham</surname><given-names>MH</given-names></name><name><surname>Dickerson</surname><given-names>D</given-names></name><name><surname>Prescott</surname><given-names>AR</given-names></name><name><surname>Abidi</surname><given-names>N</given-names></name><name><surname>Xirodimas</surname><given-names>DP</given-names></name><name><surname>Hay</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antibody RING-mediated destruction of endogenous proteins</article-title><source>Molecular Cell</source><volume>79</volume><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.04.032</pub-id><pub-id pub-id-type="pmid">32454028</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>D</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Proteasomal degradation of RPN4 via two distinct mechanisms, ubiquitin-dependent and -independent</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>23851</fpage><lpage>23854</lpage><pub-id pub-id-type="doi">10.1074/jbc.C400111200</pub-id><pub-id pub-id-type="pmid">15090546</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Romera-Paredes</surname><given-names>B</given-names></name><name><surname>Nikolov</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Pacholska</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>T</given-names></name><name><surname>Bodenstein</surname><given-names>S</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Vinyals</surname><given-names>O</given-names></name><name><surname>Senior</surname><given-names>AW</given-names></name><name><surname>Kavukcuoglu</surname><given-names>K</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloppsteck</surname><given-names>P</given-names></name><name><surname>Ewens</surname><given-names>CA</given-names></name><name><surname>Förster</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Freemont</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation of p97 in the ubiquitin-proteasome system by the UBX protein-family</article-title><source>Biochimica et Biophysica Acta</source><volume>1823</volume><fpage>125</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.09.006</pub-id><pub-id pub-id-type="pmid">21963883</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Manno</surname><given-names>A</given-names></name><name><surname>Kakizuka</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Involvement of valosin-containing protein (VCP)/p97 in the formation and clearance of abnormal protein aggregates</article-title><source>Genes to Cells</source><volume>12</volume><fpage>889</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2443.2007.01099.x</pub-id><pub-id pub-id-type="pmid">17584300</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konstantinidou</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Shaabani</surname><given-names>S</given-names></name><name><surname>Ter Brake</surname><given-names>F</given-names></name><name><surname>Essa</surname><given-names>K</given-names></name><name><surname>Dömling</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PROTACs- a game-changing technology</article-title><source>Expert Opinion on Drug Discovery</source><volume>14</volume><fpage>1255</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1080/17460441.2019.1659242</pub-id><pub-id pub-id-type="pmid">31538491</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Körner</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>H</given-names></name><name><surname>Kraus</surname><given-names>F</given-names></name><name><surname>Pfeuffer</surname><given-names>T</given-names></name><name><surname>Spielhaupter</surname><given-names>S</given-names></name><name><surname>Oeljeklaus</surname><given-names>S</given-names></name><name><surname>Schülein-Völk</surname><given-names>C</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Warscheid</surname><given-names>B</given-names></name><name><surname>Buchberger</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>p97/VCP is required for piecemeal autophagy of aggresomes</article-title><source>Nature Communications</source><volume>16</volume><elocation-id>4243</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-025-59556-x</pub-id><pub-id pub-id-type="pmid">40335532</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyano</surname><given-names>F</given-names></name><name><surname>Yamano</surname><given-names>K</given-names></name><name><surname>Kosako</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Fujiki</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Parkin-mediated ubiquitylation redistributes MITOL/March5 from mitochondria to peroxisomes</article-title><source>EMBO Reports</source><volume>20</volume><elocation-id>e47728</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201947728</pub-id><pub-id pub-id-type="pmid">31602805</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Espay</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Disease modification in parkinson’s disease: current approaches, challenges, and future considerations</article-title><source>Movement Disorders</source><volume>33</volume><fpage>660</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1002/mds.27360</pub-id><pub-id pub-id-type="pmid">29644751</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Dang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex</article-title><source>Acta Pharmacologica Sinica</source><volume>42</volume><fpage>1556</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-00605-0</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Hogenhout</surname><given-names>SA</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Ubiquitin-independent degradation: an emerging PROTAC approach?</article-title><source>BioEssays</source><volume>47</volume><elocation-id>e202400161</elocation-id><pub-id pub-id-type="doi">10.1002/bies.202400161</pub-id><pub-id pub-id-type="pmid">39600079</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukas</surname><given-names>C</given-names></name><name><surname>Savic</surname><given-names>V</given-names></name><name><surname>Bekker-Jensen</surname><given-names>S</given-names></name><name><surname>Doil</surname><given-names>C</given-names></name><name><surname>Neumann</surname><given-names>B</given-names></name><name><surname>Pedersen</surname><given-names>RS</given-names></name><name><surname>Grøfte</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>KL</given-names></name><name><surname>Hickson</surname><given-names>ID</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name><name><surname>Lukas</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress</article-title><source>Nature Cell Biology</source><volume>13</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1038/ncb2201</pub-id><pub-id pub-id-type="pmid">21317883</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macartney</surname><given-names>TJ</given-names></name><name><surname>Sapkota</surname><given-names>GP</given-names></name><name><surname>Fulcher</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An affinity-directed protein missile (AdPROM) system for targeted destruction of endogenous proteins</article-title><source>Bio-Protocol</source><volume>7</volume><elocation-id>e2614</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2614</pub-id><pub-id pub-id-type="pmid">34595287</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makaros</surname><given-names>Y</given-names></name><name><surname>Raiff</surname><given-names>A</given-names></name><name><surname>Timms</surname><given-names>RT</given-names></name><name><surname>Wagh</surname><given-names>AR</given-names></name><name><surname>Gueta</surname><given-names>MI</given-names></name><name><surname>Bekturova</surname><given-names>A</given-names></name><name><surname>Guez-Haddad</surname><given-names>J</given-names></name><name><surname>Brodsky</surname><given-names>S</given-names></name><name><surname>Opatowsky</surname><given-names>Y</given-names></name><name><surname>Glickman</surname><given-names>MH</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name><name><surname>Koren</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Ubiquitin-independent proteasomal degradation driven by C-degron pathways</article-title><source>Molecular Cell</source><volume>83</volume><fpage>1921</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2023.04.023</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masoud</surname><given-names>GN</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HIF-1α pathway: role, regulation and intervention for cancer therapy</article-title><source>Acta Pharmaceutica Sinica. B</source><volume>5</volume><fpage>378</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2015.05.007</pub-id><pub-id pub-id-type="pmid">26579469</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGettrick</surname><given-names>AF</given-names></name><name><surname>O’Neill</surname><given-names>LAJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Role of HIF in immunity and inflammation</article-title><source>Cell Metabolism</source><volume>32</volume><fpage>524</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.08.002</pub-id><pub-id pub-id-type="pmid">32853548</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLelland</surname><given-names>G-L</given-names></name><name><surname>Goiran</surname><given-names>T</given-names></name><name><surname>Yi</surname><given-names>W</given-names></name><name><surname>Dorval</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>CX</given-names></name><name><surname>Lauinger</surname><given-names>ND</given-names></name><name><surname>Krahn</surname><given-names>AI</given-names></name><name><surname>Valimehr</surname><given-names>S</given-names></name><name><surname>Rakovic</surname><given-names>A</given-names></name><name><surname>Rouiller</surname><given-names>I</given-names></name><name><surname>Durcan</surname><given-names>TM</given-names></name><name><surname>Trempe</surname><given-names>J-F</given-names></name><name><surname>Fon</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy</article-title><source>eLife</source><volume>7</volume><elocation-id>e32866</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.32866</pub-id><pub-id pub-id-type="pmid">29676259</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNaught</surname><given-names>KS</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Halliwell</surname><given-names>B</given-names></name><name><surname>Isacson</surname><given-names>O</given-names></name><name><surname>Jenner</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Failure of the ubiquitin-proteasome system in Parkinson’s disease</article-title><source>Nature Reviews. Neuroscience</source><volume>2</volume><fpage>589</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1038/35086067</pub-id><pub-id pub-id-type="pmid">11484002</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merchant</surname><given-names>KM</given-names></name><name><surname>Cedarbaum</surname><given-names>JM</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><name><surname>Dave</surname><given-names>KD</given-names></name><name><surname>Eberling</surname><given-names>J</given-names></name><name><surname>Espay</surname><given-names>AJ</given-names></name><name><surname>Hutten</surname><given-names>SJ</given-names></name><name><surname>Javidnia</surname><given-names>M</given-names></name><name><surname>Luthman</surname><given-names>J</given-names></name><name><surname>Maetzler</surname><given-names>W</given-names></name><name><surname>Menalled</surname><given-names>L</given-names></name><name><surname>Reimer</surname><given-names>AN</given-names></name><name><surname>Stoessl</surname><given-names>AJ</given-names></name><name><surname>Weiner</surname><given-names>DM</given-names></name><collab>The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group</collab></person-group><year iso-8601-date="2019">2019</year><article-title>A proposed roadmap for parkinson’s disease proof of concept clinical trials investigating compounds targeting alpha-synuclein</article-title><source>Journal of Parkinson’s Disease</source><volume>9</volume><fpage>31</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.3233/JPD-181471</pub-id><pub-id pub-id-type="pmid">30400107</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>p97 complexes as signal integration hubs</article-title><source>BMC Biology</source><volume>10</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7007-10-48</pub-id><pub-id pub-id-type="pmid">22694940</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>H</given-names></name><name><surname>Bug</surname><given-names>M</given-names></name><name><surname>Bremer</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system</article-title><source>Nature Cell Biology</source><volume>14</volume><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1038/ncb2407</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>JH</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Ivan</surname><given-names>M</given-names></name><name><surname>Gertler</surname><given-names>F</given-names></name><name><surname>Kaelin</surname><given-names>WG</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling</article-title><source>Science</source><volume>296</volume><fpage>1886</fpage><lpage>1889</lpage><pub-id pub-id-type="doi">10.1126/science.1073440</pub-id><pub-id pub-id-type="pmid">12004076</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Mirdita</surname><given-names>M</given-names></name><name><surname>Schütze</surname><given-names>K</given-names></name><name><surname>Moriwaki</surname><given-names>Y</given-names></name><name><surname>Heo</surname><given-names>L</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ColabFold - making protein folding accessible to all</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.08.15.456425</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Kakizuka</surname><given-names>A</given-names></name><name><surname>Okamoto</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Vacuole-creating protein in neurodegenerative diseases in humans</article-title><source>Neuroscience Letters</source><volume>343</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(03)00280-5</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukkavalli</surname><given-names>S</given-names></name><name><surname>Klickstein</surname><given-names>JA</given-names></name><name><surname>Ortiz</surname><given-names>B</given-names></name><name><surname>Juo</surname><given-names>P</given-names></name><name><surname>Raman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The p97-UBXN1 complex regulates aggresome formation</article-title><source>Journal of Cell Science</source><volume>134</volume><elocation-id>jcs254201</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.254201</pub-id><pub-id pub-id-type="pmid">33712450</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>IM</given-names></name><name><surname>Szyniarowski</surname><given-names>P</given-names></name><name><surname>Toth</surname><given-names>R</given-names></name><name><surname>Rouse</surname><given-names>J</given-names></name><name><surname>Lachaud</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved genome editing in human cell lines using the CRISPR method</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e109752</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109752</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noi</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>D</given-names></name><name><surname>Nishikori</surname><given-names>S</given-names></name><name><surname>Arita-Morioka</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>T</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High-speed atomic force microscopic observation of ATP-dependent rotation of the AAA+ chaperone p97</article-title><source>Structure</source><volume>21</volume><fpage>1992</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1016/j.str.2013.08.017</pub-id><pub-id pub-id-type="pmid">24055316</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olszewski</surname><given-names>MM</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>KC</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Cdc48 unfoldase prepares well-folded protein substrates for degradation by the 26S proteasome</article-title><source>Communications Biology</source><volume>2</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-019-0283-z</pub-id><pub-id pub-id-type="pmid">30675527</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottis</surname><given-names>P</given-names></name><name><surname>Toure</surname><given-names>M</given-names></name><name><surname>Cromm</surname><given-names>PM</given-names></name><name><surname>Ko</surname><given-names>E</given-names></name><name><surname>Gustafson</surname><given-names>JL</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Assessing different E3 ligases for small molecule induced protein ubiquitination and degradation</article-title><source>ACS Chemical Biology</source><volume>12</volume><fpage>2570</fpage><lpage>2578</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00485</pub-id><pub-id pub-id-type="pmid">28767222</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paiva</surname><given-names>SL</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeted protein degradation: elements of PROTAC design</article-title><source>Current Opinion in Chemical Biology</source><volume>50</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2019.02.022</pub-id><pub-id pub-id-type="pmid">31004963</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Ai</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20359-x</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pankey</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Infective endocarditis: changing concepts</article-title><source>Hospital Practice</source><volume>21</volume><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1080/21548331.1986.11704941</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pessina</surname><given-names>F</given-names></name><name><surname>Giavazzi</surname><given-names>F</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Gioia</surname><given-names>U</given-names></name><name><surname>Vitelli</surname><given-names>V</given-names></name><name><surname>Galbiati</surname><given-names>A</given-names></name><name><surname>Barozzi</surname><given-names>S</given-names></name><name><surname>Garre</surname><given-names>M</given-names></name><name><surname>Oldani</surname><given-names>A</given-names></name><name><surname>Flaus</surname><given-names>A</given-names></name><name><surname>Cerbino</surname><given-names>R</given-names></name><name><surname>Parazzoli</surname><given-names>D</given-names></name><name><surname>Rothenberg</surname><given-names>E</given-names></name><name><surname>d’Adda di Fagagna</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Functional transcription promoters at DNA double-strand breaks mediate RNA-driven phase separation of damage-response factors</article-title><source>Nature Cell Biology</source><volume>21</volume><fpage>1286</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0392-4</pub-id><pub-id pub-id-type="pmid">31570834</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas-Fernandez</surname><given-names>A</given-names></name><name><surname>Herhaus</surname><given-names>L</given-names></name><name><surname>Macartney</surname><given-names>T</given-names></name><name><surname>Lachaud</surname><given-names>C</given-names></name><name><surname>Hay</surname><given-names>RT</given-names></name><name><surname>Sapkota</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Rapid generation of endogenously driven transcriptional reporters in cells through CRISPR/Cas9</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>9811</elocation-id><pub-id pub-id-type="doi">10.1038/srep09811</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Poirier</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Protein aggregation and neurodegenerative disease</article-title><source>Nature Medicine</source><volume>10 Suppl</volume><fpage>S10</fpage><lpage>S17</lpage><pub-id pub-id-type="doi">10.1038/nm1066</pub-id><pub-id pub-id-type="pmid">15272267</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Röth</surname><given-names>S</given-names></name><name><surname>Macartney</surname><given-names>TJ</given-names></name><name><surname>Konopacka</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>K-H</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Queisser</surname><given-names>MA</given-names></name><name><surname>Sapkota</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting endogenous K-RAS for degradation through the affinity-directed protein missile system</article-title><source>Cell Chemical Biology</source><volume>27</volume><fpage>1151</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2020.06.012</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>I</given-names></name><name><surname>Yuste-Checa</surname><given-names>P</given-names></name><name><surname>Da Silva Padilha</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Körner</surname><given-names>R</given-names></name><name><surname>Holthusen</surname><given-names>H</given-names></name><name><surname>Trinkaus</surname><given-names>VA</given-names></name><name><surname>Dudanova</surname><given-names>I</given-names></name><name><surname>Fernández-Busnadiego</surname><given-names>R</given-names></name><name><surname>Baumeister</surname><given-names>W</given-names></name><name><surname>Sanders</surname><given-names>DW</given-names></name><name><surname>Gautam</surname><given-names>S</given-names></name><name><surname>Diamond</surname><given-names>MI</given-names></name><name><surname>Hartl</surname><given-names>FU</given-names></name><name><surname>Hipp</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>560</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-36058-2</pub-id><pub-id pub-id-type="pmid">36732333</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Kumagai</surname><given-names>A</given-names></name><name><surname>Mercurio</surname><given-names>F</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name><name><surname>Deshaies</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation</article-title><source>PNAS</source><volume>98</volume><fpage>8554</fpage><lpage>8559</lpage><pub-id pub-id-type="doi">10.1073/pnas.141230798</pub-id><pub-id pub-id-type="pmid">11438690</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>MF</given-names></name><name><surname>Gan</surname><given-names>ZY</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name><name><surname>Dewson</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities</article-title><source>Cell Death and Differentiation</source><volume>28</volume><fpage>570</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-00706-7</pub-id><pub-id pub-id-type="pmid">33414510</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shein</surname><given-names>M</given-names></name><name><surname>Hitzenberger</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>TC</given-names></name><name><surname>Rout</surname><given-names>SR</given-names></name><name><surname>Leitl</surname><given-names>KD</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Zacharias</surname><given-names>M</given-names></name><name><surname>Sakata</surname><given-names>E</given-names></name><name><surname>Schütz</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Characterizing ATP processing by the AAA+ protein p97 at the atomic level</article-title><source>Nature Chemistry</source><volume>16</volume><fpage>363</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1038/s41557-024-01440-0</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>LM</given-names></name><name><surname>Macartney</surname><given-names>TJ</given-names></name><name><surname>Nardin</surname><given-names>A</given-names></name><name><surname>Fulcher</surname><given-names>LJ</given-names></name><name><surname>Röth</surname><given-names>S</given-names></name><name><surname>Testa</surname><given-names>A</given-names></name><name><surname>Maniaci</surname><given-names>C</given-names></name><name><surname>Ciulli</surname><given-names>A</given-names></name><name><surname>Ganley</surname><given-names>IG</given-names></name><name><surname>Sapkota</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inducible degradation of target proteins through a tractable affinity-directed protein missile system</article-title><source>Cell Chemical Biology</source><volume>27</volume><fpage>1164</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2020.06.013</pub-id><pub-id pub-id-type="pmid">32668203</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>BE</given-names></name><name><surname>Wang</surname><given-names>SL</given-names></name><name><surname>Jaime-Figueroa</surname><given-names>S</given-names></name><name><surname>Harbin</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hamman</surname><given-names>BD</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>131</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08027-7</pub-id><pub-id pub-id-type="pmid">30631068</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stach</surname><given-names>L</given-names></name><name><surname>Freemont</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The AAA+ ATPase p97, a cellular multitool</article-title><source>The Biochemical Journal</source><volume>474</volume><fpage>2953</fpage><lpage>2976</lpage><pub-id pub-id-type="doi">10.1042/BCJ20160783</pub-id><pub-id pub-id-type="pmid">28819009</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tara</surname><given-names>CS</given-names></name><name><surname>Stanley</surname><given-names>JA</given-names></name><name><surname>Kucera</surname><given-names>LS</given-names></name><name><surname>Hollis</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1974">1974</year><article-title>Photodynamic inactivation of herpes simplex keratitis</article-title><source>Archives of Ophthalmology</source><volume>92</volume><fpage>51</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1001/archopht.1974.01010010055013</pub-id><pub-id pub-id-type="pmid">4835977</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomoshige</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>S</given-names></name><name><surname>Ohgane</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Ishikawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Discovery of small molecules that induce the degradation of huntingtin</article-title><source>Angewandte Chemie</source><volume>56</volume><fpage>11530</fpage><lpage>11533</lpage><pub-id pub-id-type="doi">10.1002/anie.201706529</pub-id><pub-id pub-id-type="pmid">28703441</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomoshige</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs)</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>41</volume><elocation-id>116221</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmc.2021.116221</pub-id><pub-id pub-id-type="pmid">34034148</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>M</given-names></name><name><surname>Harkness</surname><given-names>RW</given-names></name><name><surname>Ripstein</surname><given-names>ZA</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Vahidi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Allosteric regulation of proteolytic machines unveiled by the synergy between cryo-EM and solution NMR spectroscopy</article-title><source>Biochemical Journal</source><volume>482</volume><fpage>1229</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1042/BCJ20253239</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Boom</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>VCP/p97-mediated unfolding as a principle in protein homeostasis and signaling</article-title><source>Molecular Cell</source><volume>69</volume><fpage>182</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.10.028</pub-id><pub-id pub-id-type="pmid">29153394</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Degradation of proteins by PROTACs and other strategies</article-title><source>Acta Pharmaceutica Sinica B</source><volume>10</volume><fpage>207</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2019.08.001</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>GDJ</given-names></name><name><surname>Wymer</surname><given-names>J</given-names></name><name><surname>Kovach</surname><given-names>MJ</given-names></name><name><surname>Mehta</surname><given-names>SG</given-names></name><name><surname>Mumm</surname><given-names>S</given-names></name><name><surname>Darvish</surname><given-names>D</given-names></name><name><surname>Pestronk</surname><given-names>A</given-names></name><name><surname>Whyte</surname><given-names>MP</given-names></name><name><surname>Kimonis</surname><given-names>VE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein</article-title><source>Nature Genetics</source><volume>36</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/ng1332</pub-id><pub-id pub-id-type="pmid">15034582</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wentink</surname><given-names>A</given-names></name><name><surname>Rosenzweig</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Protein disaggregation machineries in the human cytosol</article-title><source>Current Opinion in Structural Biology</source><volume>83</volume><elocation-id>102735</elocation-id><pub-id pub-id-type="doi">10.1016/j.sbi.2023.102735</pub-id><pub-id pub-id-type="pmid">38000128</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>McClatchy</surname><given-names>DB</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Diedrich</surname><given-names>J</given-names></name><name><surname>Sanchez-Alavez</surname><given-names>M</given-names></name><name><surname>Petrascheck</surname><given-names>M</given-names></name><name><surname>Yates</surname><given-names>JR</given-names><suffix>III</suffix></name><name><surname>Cline</surname><given-names>HT</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Activity-Dependent Synthesis of Emerin Gates Neuronal Plasticity by Regulating Proteostasis</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.06.30.600712</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sequestration of cellular interacting partners by protein aggregates: implication in a loss-of-function pathology</article-title><source>The FEBS Journal</source><volume>283</volume><fpage>3705</fpage><lpage>3717</lpage><pub-id pub-id-type="doi">10.1111/febs.13722</pub-id><pub-id pub-id-type="pmid">27016044</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>WK</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A mighty “protein extractor” of the cell: structure and function of the p97/CDC48 ATPase</article-title><source>Frontiers in Molecular Biosciences</source><volume>4</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2017.00039</pub-id><pub-id pub-id-type="pmid">28660197</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hypoxia and aging</article-title><source>Experimental &amp; Molecular Medicine</source><volume>51</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s12276-019-0233-3</pub-id><pub-id pub-id-type="pmid">31221957</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>HO</given-names></name><name><surname>Kloppsteck</surname><given-names>P</given-names></name><name><surname>Niwa</surname><given-names>H</given-names></name><name><surname>Isaacson</surname><given-names>RL</given-names></name><name><surname>Matthews</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Freemont</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Insights into adaptor binding to the AAA protein p97</article-title><source>Biochemical Society Transactions</source><volume>36</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1042/BST0360062</pub-id><pub-id pub-id-type="pmid">18208387</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Geng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Ichida</surname><given-names>Y</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Pozo</surname><given-names>FM</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wozniak</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Miyagi</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>53BP1 regulates heterochromatin through liquid phase separation</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>360</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28019-y</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Pittman</surname><given-names>S</given-names></name><name><surname>Dhavale</surname><given-names>D</given-names></name><name><surname>French</surname><given-names>R</given-names></name><name><surname>Patterson</surname><given-names>JN</given-names></name><name><surname>Kaleelurrrahuman</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Buscher</surname><given-names>WJ</given-names></name><name><surname>Bieschke</surname><given-names>J</given-names></name><name><surname>Kotzbauer</surname><given-names>P</given-names></name><name><surname>Ayala</surname><given-names>Y</given-names></name><name><surname>Davis</surname><given-names>AA</given-names></name><name><surname>Weihl</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>VCP protects neurons from proteopathic seeding</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.07.12.452081</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101496.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Yihong</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This study describes a valuable PROTAC approach in which the UBX domain of FAF1 fused to a nanobody (Ubx-Nb) can target protein of interest for degradation. The authors provide convincing evidence, showing that Ubx-Nb with a nanobody recognizing GFP can reduce the cellular levels of several GFP-fusion model substrates including some aggregation-prone proteins relevant to neurodegenerative diseases. The study will be of broad interest to cell biologists in the targeted protein degradation field.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101496.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ye</surname><given-names>Yihong</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101496.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Evidence, reproducibility and clarity):</p><p>The paper by Salinas-Rebolledo et al. describes a novel PROTAC approach in which the UBX domain of FAF1 is fused to a nanobody that recognizes the target protein. The idea is that the UBX domain will bind the fusion protein to the p97 ATPase, a major ATPase involved in the unfolding of many proteins. The target protein recognized by the UBX-nanobody fusion (UBXNb) is then supposed to be unfolded in a ubiquitin-independent manner and subsequently degraded by the proteasome.</p><p>The authors provide evidence that Ubx-Nb, containing a nanobody recognizing GFP, can colocalize with GFP fusion proteins in the nucleus and to liquid-liquid phase separation structures. Importantly, the fusion can reduce the cellular levels of the target proteins. The authors confirm that degradation triggered by Ubx-Nb is proteasome dependent. Ubx-Nb can also promote the degradation of model proteins that form aggregates relevant to neurodegenerative diseases.</p><p>The major issue with the paper is that it does not provide mechanistic insight into the degradation mechanism. First, the data implicating p97 in degradation are conflicting. On the one hand, siRNA of p97 compromises degradation (although degradation is not completely inhibited; see Figure 4G), but on the other hand, an inhibitor of p97 does not have an effect. The authors have not shown that target proteins are actually unfolded by their artificial adaptor (in vitro experiments would be required).</p><p>In addition, it would be important to show co-localization in vivo with p97.</p><p>Thus, the role of p97 is not convincingly established. Another major question is how the unfolded, non-ubiquitinated proteins would be degraded by the 26S proteasome. Is there a ubiquitin ligase required after substrate unfolding?</p><p>Overall, the paper reports some intriguing effects of their designed PROTAC adaptor, but the mechanism by which it functions remains unclear. The findings of the manuscript appears too preliminary in its current version for it to be of value to the community.</p></disp-quote><p>We appreciate the feedback provided and acknowledge the reviewers' concerns regarding the mechanistic insight into the degradation process. Below, we address some of the point raised:</p><p>We have been working on a way to demonstrate that our technology is capable of reducing aggregate degradation using cell models available in our laboratory, and we came up with the idea of using an aggregate amplification assay with cell models. We have successfully demonstrated the ability to induce aggregate formation, and furthermore, it has also been demonstrated that fusion of UBX with GFP nanobodies is capable of reducing intracellular active aggregates of wild-type GFP-fused alphasynuclein, Figure 6E.</p><p>We acknowledge that our current data do not fully elucidate the degradation mechanism involving p97, however we unveil a practical phenomenon with potential clinical associated uses.</p><p>Regarding the ablation of p97 siRNA we do observe significant rescue of Emerin in the Figure 4G. Even more we also observed a slight increase in the levels of the UBX fused to the nanobody anti GFP indicating that even the levels of the synthetic construct are down regulated by its association to p97.</p><p>We agree that the results derivate of the used of p97 inhibitor are intriguing, regarding this matter we can only pointed that the selective inhibitor used in our study binds to the D2 domains of p97, as reported by Zhou et al. (J Med Chem. 2015). There are molecules that bind to the D1 domain and enhance p97-mediated degradation (Figuerola-Conchas et al., ACS Chem Biol. 2020). The primary ATPase function of p97 is associated with the D2 domain, but ATP binding to the D1 domain is crucial for hexamer formation and N-terminal domain conformation, which regulates cofactor binding and various functions of p97. Therefore, it is possible that our p97-PROTAC activates the D1 domain or interacts with cofactors enhancing protein degradation mediated by p97.</p><p>In order to demonstrate that proximity is sufficient for p97-mediated degradation, we performed an experiment in which a GFP-tagged p97 was overexpressed at increasing concentration and a single myc-tagged Nanobody against GFP was co-transfected. We demonstrated that the levels of the myc-tagged nanobody also decreased along the increasing concentration of GFP-tagged p97. We suggest that this experiment also supports the idea that proximity to p97 is mechanistically the most relevant feature for the p97-mediated PROTAC we presented in this manuscript (Supplemental Figure 1H and 1I).</p><p>We added a co-localization profiles into the supplemental Figure 1A, 1B and 1C between the targets protein and the p97-PROTAC. However, the in vivo application feld out of the scope of this manuscript.</p><p>In order to demonstrate that the p97-PROTAC-mediated degradation occurs in a ubiquitin-independent manner, we used the Ubiquitin E1 inhibitor Pyr-41. We selected p53 as a model, which is a constitutively degraded protein in Hela cells by the viral complex E6AP/E6. We determined the concentration at which ubiquitination was decreased to the point where p53 accumulation was observed (Supplemental Figure 1G). Further, a similar concentration of the inhibitor was used in a p97-mediated degradation assay in Figure 4G. Since we did not observe the inhibitory effect on the degradation, we concluded that this is a process independent of ubiquitination, either before or after the protein could be unfolded by p97.</p><p>Previous evidence suggests that some other protein can be directed to the proteasome via both ubiquitin-dependent and ubiquitin-independent mechanisms. For instance, Butler et al. (2016) demonstrated that fusing NbSyn87 with the mouse Ornithine Decarboxylase (ODC) PEST degron effectively reduced protein levels and this reduction was achieved by harnessing the innate cellular machinery responsible for ubiquitin-independent proteolysis.</p><list list-type="bullet" id="list1"><list-item><p>Makaros Y, Raiff A, Timms RT, Wagh AR, Gueta MI, Bekturova A, Guez-Haddad J, Brodsky S, Opatowsky Y, Glickman MH, Elledge SJ, Koren I. Ubiquitin-independent proteasomal degradation driven by C-degron pathways. Mol Cell. 2023 Jun 1;83(11):1921-1935.e7. doi: 10.1016/j.molcel.2023.04.023. Epub 2023 May 17. PMID: 37201526; PMCID: PMC10237035.</p></list-item><list-item><p>Butler DC, Joshi SN, Genst E, Baghel AS, Dobson CM, Messer A. Bifunctional Anti-NonAmyloid Component α-Synuclein Nanobodies Are Protective In Situ. PLoS One. 2016 Nov 8;11(11):e0165964. doi: 10.1371/journal.pone.0165964. PMID: 27824888; PMCID: PMC5100967.</p></list-item><list-item><p>Erales J, Coffino P. Ubiquitin-independent proteasomal degradation. Biochim Biophys Acta. 2014 Jan;1843(1):216-21. doi: 10.1016/j.bbamcr.2013.05.008. Epub 2013 May 14. PMID: 23684952; PMCID: PMC3770795.</p></list-item><list-item><p>Donghong Ju, Youming Xie, Proteasomal Degradation of RPN4 via Two Distinct Mechanisms, Ubiquitin-dependent and -independent*, Journal of Biological Chemistry, Volume 279, Issue 23, 2004, Pages 23851-23854, ISSN 0021-9258.</p></list-item></list><p>We also speculate that the degradation may also occur via the autophagy-lysosome pathway. These speculations will be added to the Discussion section, and we plan to investigate this pathway in detail in a subsequent scientific article focused on the mechanism of action of p97-PROTAC.</p><p>We believe that our findings present an innovative and unique tool, we appreciate the reviewers' comments and hope that our detailed response and future research plans address their concerns.</p><disp-quote content-type="editor-comment"><p>Minor points:</p><p>Figure 1B: Although emerin is reported to be a nuclear envelope protein, it is not localized to the NE, but throughout the ER, likely because the protein was too highly expressed.</p></disp-quote><p>We agree with the reviewer that overexpression can lead to undesirable effects, in this case low transfection levels (0.5 ug DNA) were used, and the localization was observed in the nuclear membrane and ER, as reported in several cell lines even under endogenous levels: https://www.proteinatlas.org/ENSG00000102119-EMD/subcellular. To further support this observation, we have included an additional reference in the manuscript.</p><disp-quote content-type="editor-comment"><p>Figure 1B: ETV co-localization is not obvious from the figure.</p></disp-quote><p>We have included histograms for the colocalization in the supplemental Figure 1A, 1B and 1C to highlight the co-localization reported</p><disp-quote content-type="editor-comment"><p>Figure 4: The depletion of p97 leads to cell death, so it is unclear whether the siRNA effect is specific.</p></disp-quote><p>We appreciate your comment and would like to clarify that there are published studies where the p97 gene has been silenced in HeLa cells without causing complete cell death for an specific time frame, we also like to highlight that siRNA ablation in combination with western blot analysis is a very sensitive technique but it´s not a demonstration of a full depletion as it would be the generation of Knock out cellular models.</p><p>Reported studies</p><list list-type="bullet" id="list2"><list-item><p>Wójcik C, Yano M, DeMartino GN. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Cell Sci. 2004 Jan 15;117(Pt 2):281-92. doi: 10.1242/jcs.00841. Epub 2003 Dec 2. PMID: 14657277.</p></list-item><list-item><p>Beskow A, Grimberg KB, Bott LC, Salomons FA, Dantuma NP, Young P. A conserved unfoldase activity for the p97 AAA-ATPase in proteasomal degradation. J Mol Biol. 2009 Dec 11;394(4):732-46. doi: 10.1016/j.jmb.2009.09.050. Epub 2009 Sep 24. PMID: 19782090.</p></list-item><list-item><p>Yahiro K, Tsutsuki H, Ogura K, Nagasawa S, Moss J, Noda M. Regulation of subtilase cytotoxin-induced cell death by an RNA-dependent protein kinase-like endoplasmic reticulum kinase-dependent proteasome pathway in HeLa cells. Infect Immun. 2012 May;80(5):1803-14. doi: 10.1128/IAI.06164-11. Epub 2012 Feb 21. PMID: 22354021; PMCID: PMC3347452.</p></list-item></list><disp-quote content-type="editor-comment"><p>Figure 5C: The colocalization of GFP-HTT Q23 with UBX-Nb(GFP) is not entirely convincing.</p></disp-quote><p>In this particular case the GFP-HTT Q23 is distribute in the cytoplasm and it´s does not accumulates in structures that could reference as references to high light the colocalization.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Significance):</p><p>Overall, the paper reports some intriguing effects of their designed PROTAC adaptor, but the mechanism by which it functions remains unclear. The findings of the manuscript appears too preliminary in its current version for it to be of value to the community.</p><p>Reviewer #2 (Evidence, reproducibility and clarity (Required)):</p><p>Summary:</p><p>The authors have developed a p97-directed proteolysis-targeting chimera (PROTAC) that operates independently of ubiquitin. This system employs a camelid nanobody to selectively recognize target proteins, tethered to p97 through the UBX domain of the p97 adapter FAF1. The anti-GFP nanobody effectively targets various GFP-fusion proteins for degradation via the proteasome, relying on p97 for its mechanism of action. The authors validate the presence of p97 in brain tissues of Non-Human Primates (Nhp) Macaca fascicularis, rat (Sprague Dawley), and mouse (C57BL6/C), supported by proteasome inhibition and p97 RNA silencing data. Importantly, the p97-PROTAC mechanism operates independently of ubiquitination, demonstrated through degradation of clinically relevant proteins such as α-synuclein using a camelid nanobody (NbSyn87).</p><p>Major comments:</p><p>Anti-GFP Nanobody clarification: Details about the original anti-GFP nanobody are unclear, which makes reproducing the current work a challenge for outside labs.</p><p>20. Fulcher LJ, Macartney T, Bozatzi P, Hornberger A, Rojas-Fernandez A, Sapkota GP. An affinity-directed protein missile system for targeted proteolysis. Open Biol. Oct 2016;6(10)doi:10.1098/rsob.160255 o I assume that the anti-GFP nanobody is aGFP from supplementary figure #2 in the Fulcher manuscript but is unclear as they also have used anti-GFP nanobody aGFP16.</p><p>Amino acids from FAF1-UBX domain: Further clarity is needed regarding the amino acid details from the FAF1-UBX domain, which may have been disclosed in a patent application but should be explicitly outlined in the methods section.</p></disp-quote><p>We appreciate the comment regarding the need for further clarity on the amino acid details from the FAF1-UBX domain. To address this, we have added a supplementary figure which includes a table outlining the amino acid sequences of our construct and the FAF1-UBX domain. This supplementary figure 1 provides a detailed representation of the amino acid sequences. We hope this addition meets your requirements and provides the necessary information for a comprehensive understanding of our work. We also cited the studies from Fulcher et all accordingly.</p><disp-quote content-type="editor-comment"><p>Degradation of Proteins of Clinical Interest: The data presented is not convincing enough to support the stated claims that the PROTAC is clearing aggregated mutant HTT. In Figure 5, there is an abundance of GFP-HTT Q74 puncta. While the western blot data suggests a reduction of soluble GFP-HTT-Q74 protein levels, it does not account for aggregated HTT. Aggregated HTT does not efficiently enter the separating gel during electrophoresis. To make these claims the authors need to 1. Show the level of mHTT Q74 aggregation in the empty control groups so that a comparison can be visually made between empty control groups and UBX-Nb(GFP) treated groups. A similar comparison would be useful with the GFP-HTT Q23 treated cells as well.</p><p>Visualization of Aggregated Proteins: The continued visibility of puncta raises doubts about the system's efficacy in degrading aggregated proteins. Including comparisons between untreated and treated cells for all test systems would strengthen the argument. It would be useful to show a comparison between the untreated controls and UBX-Nb (GFP) treated cells for all the test systems shown.</p></disp-quote><p>We acknowledge that the data presented in Figure 5 may not be sufficient to support the claim that the PROTAC is clearing aggregated mutant HTT. The western blot data suggests a reduction in soluble GFP-HTT-Q74 protein levels, but it does not account for aggregated HTT, which does not efficiently enter the separating gel during electrophoresis.</p><p>To address this, we conducted additional experiments using Q24-Htt, where we observed the aggregates of huntingtin and the reduction of high molecular weight aggregates upon treatment with UBX-Nb (Supplemental Figure-2B). We also attempt and spend several months implementing the RT-QuIC system to determine the reduction of seeds and aggregates in cells, however the experimental setting is very variable and not fully reproducible at this stage. Regardless our strong commitment to directly demonstrating the reduction of the active seeds and toxic aggregates remain to be solved. We also believe that in vitro reconstitution could be a direct manner to measure the effect of the p97-PROTAC. However, unfortunately, this approach fell outside of the scope of this study.</p><p>To demonstrate the reduction of aggregates in tissue culture, we adapted the RealTime Quaking-Induced Conversion (RT-QuIC) assay, a highly sensitive method for amplifying α-synuclein aggregates to detect and quantify intracellular aggregates. Initially, we confirmed that transient transfection increases aggregate levels, which can be directly measured using this method. We then assessed the effect of UBX fused to Nanobody 87 and UBX fused to a GFP-targeting nanobody on aggregate seeding. While UBX-Nanobody 87 showed a tendency to reduce aggregate seeding, UBX-GFP nanobody significantly decreased intracellular aggregate levels. This assay required several months of optimization, but we are pleased to present a useful adaptation of the RT-QuIC method along with evidence that UBX-nanobody fusions can effectively reduce protein aggregation.</p><p>We additionally demonstrate that our technology is capable of reducing aggregate degradation using cell models available for the induction of intracellular aggregates of α synuclein and associated to aggregates amplification assay with cell models. We have successfully demonstrated the ability to induce aggregate formation in cells, and furthermore, it has also been demonstrated that fusion of UBX with GFP nanobodies is capable of reducing intracellular active aggregates of wild-type GFP-fused alphasynuclein, Figure 6E.</p><disp-quote content-type="editor-comment"><p>Minor comments:</p><p>The In-text citations should be placed outside of the sentence. Example: The ubiquitin proteasome system (UPS) regulates protein abundance by specific E3 ubiquitin ligases, which catalyze ubiquitin chain formation on the substrates, inducing their proteasome mediated degradation. 1-4</p><p>Sentence two in the introduction is missing a period. It is unclear whether sentence three is a heading or part of paragraph one.</p><p>There are additional formatting issues. It would be easier to read the paper if there was a space between paragraphs. Page numbers would be helpful.</p><p>Page 2. Missing word. Inclusion body myopathy associated with Paget's disease.</p><p>Figure 1. D, F, and E. Missing annotation to denote significance.</p><p>Figure 2G Missing annotation to denote significance.</p><p>Figure 4. Missing annotation to denote significance for figures 4D, 4F, 4H.</p><p>Is Figure 4I significantly different or not? In Figure 6, you use ns to denote not significant. This feels like it is an important point that you would want to make that the effect is dependent on p97. When you knock out p97 the degradation capacity of UBX-Nb is lost.</p></disp-quote><p>We appreciate your careful review and constructive feedback. We have addressed all the minor comments as follows:</p><p>Citations: We have revised the placement of citations throughout the manuscript to ensure they are positioned outside the sentence.</p><p>Introduction and Formatting: We have corrected the introduction and improved the manuscript’s readability by adding spaces between paragraphs and including page numbers for better navigation.</p><p>Page 4: We have corrected the missing word in &quot;Inclusion body myopathy associated with Paget's disease of bone and Frontotemporal Dementia (IBMPFD).&quot;</p><p>Figure Annotations: We have added the missing significance annotations in Figures 1D, 1F, and 1E. We have included the appropriate significance annotations in Figure 2G. We have revised Figure 4 to ensure significance annotations are present for Figures 4D, 4F, and 4H. Also, we have clarified that Figure 4H shows a significant difference, emphasizing that when p97 is knocked out, the degradation capacity of UBX-Nb is lost. We have ensured that the data presentation clearly reflects the dependence on p97. And finally, for Figure 4I, we have used &quot;ns&quot; to denote non-significance.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Significance):</p><p>The p97-PROTAC system is an ubiquitin-independent approach to degrade intracellular proteins. This system was able to target proteins for degradation at diverse subcellular locations, integral membrane protein residing at the inner nuclear membrane, chromatin located, and liquid-liquid phase separated compartments. The ability to clear alphasynuclein builds on previous research suggesting that ubiquitin-independent degradation of α-synuclein could be a therapeutic approach to treat synucleinopathies such as Parkinson's Disease. However, the ability of this approach to clear aggregated proteins is not convincing, given the presence of visible aggregates in the treated cells.</p><p>The investigations with NbSyn87 build upon prior research by Butler et al. (2016), who fused NbSyn87 with the mouse Ornithine decarboxylase (ODC) PEST degron. This fusion strategy not only facilitates the targeting of α-synuclein but also harnesses the innate cellular machinery responsible for ubiquitin-independent proteolysis. The current approach demonstrates and alternative mechanism to direct α-synuclein (and other proteins) into the proteasome for ubiquitin-independent clearance.</p><p>At the current state of development, this research is of interest to specialized audience with antibody engineering backgrounds; however, it holds translational potential for clearance of toxic proteins.</p><p>My research interests is in the development of therapeutics for the treatment of neurodegenerative diseases including Huntington's Disease, Parkinson's Disease, and Alzheimer's Disease.</p></disp-quote></body></sub-article></article>